
==== Front
Front Neurosci
Front Neurosci
Front. Neurosci.
Frontiers in Neuroscience
1662-4548
1662-453X
Frontiers Media S.A.

10.3389/fnins.2021.665820
Neuroscience
Review
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
Iarkov Alexandre 1 *

Mendoza Cristhian 1
Echeverria Valentina 1 2 *

1Laboratorio de Neurobiología, Facultad de Ciencias de la Salud, Universidad San Sebastián, Concepción, Chile
2Research & Development Service, Bay Pines VA Healthcare System, Bay Pines, FL, United States
Edited by: Kathleen A. Maguire-Zeiss, Georgetown University, United States

Reviewed by: Andreas Wree, University of Rostock, Germany; Roberto Cilia, Carlo Besta Neurological Institute (IRCCS), Italy

*Correspondence: Alexandre Iarkov, alexandre.iarkov@uss.cl
Valentina Echeverria, valentina.echeverria@uss.cl
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience

20 9 2021
2021
15 66582009 2 2021
26 8 2021
Copyright © 2021 Iarkov, Mendoza and Echeverria.
2021
Iarkov, Mendoza and Echeverria
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Parkinson’s disease (PD) is a neurodegenerative condition characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) in the midbrain resulting in progressive impairment in cognitive and motor abilities. The physiological and molecular mechanisms triggering dopaminergic neuronal loss are not entirely defined. PD occurrence is associated with various genetic and environmental factors causing inflammation and mitochondrial dysfunction in the brain, leading to oxidative stress, proteinopathy, and reduced viability of dopaminergic neurons. Oxidative stress affects the conformation and function of ions, proteins, and lipids, provoking mitochondrial DNA (mtDNA) mutation and dysfunction. The disruption of protein homeostasis induces the aggregation of alpha-synuclein (α-SYN) and parkin and a deficit in proteasome degradation. Also, oxidative stress affects dopamine release by activating ATP-sensitive potassium channels. The cholinergic system is essential in modulating the striatal cells regulating cognitive and motor functions. Several muscarinic acetylcholine receptors (mAChR) and nicotinic acetylcholine receptors (nAChRs) are expressed in the striatum. The nAChRs signaling reduces neuroinflammation and facilitates neuronal survival, neurotransmitter release, and synaptic plasticity. Since there is a deficit in the nAChRs in PD, inhibiting nAChRs loss in the striatum may help prevent dopaminergic neurons loss in the striatum and its pathological consequences. The nAChRs can also stimulate other brain cells supporting cognitive and motor functions. This review discusses the cholinergic system as a therapeutic target of cotinine to prevent cognitive symptoms and transition to dementia in PD.

cotinine
dementia
Parkinson’s disease
cholinergic interneurons
medium spiny neurons
striatum
Fondo Nacional de Desarrollo Científico y Tecnológico 10.13039/501100002850
==== Body
pmcIntroduction

Parkinson’s disease (PD) is a severe neurodegenerative condition characterized by the death of dopaminergic motor and non-motor symptoms leading to locomotor impairment, loss of cognitive function, dementia, psychiatric disorders, and premature death (Gelb et al., 1999; Leverenz et al., 2009; Subramaniam and Chesselet, 2013; Grover et al., 2015; Aarsland et al., 2017; Martin-Jimenez et al., 2017; Poewe et al., 2017; Walker et al., 2019; Wichmann, 2019; Hussein et al., 2021).

More than a century of studies in PD achieved breakthrough discoveries in the etiology of this disease and the role of cholinergic neurons (Quik et al., 2015b; Jurado-Coronel et al., 2016; Rizzi and Tan, 2017; Tanimura et al., 2018; Ztaou and Amalric, 2019; Iarkov et al., 2020; Liu, 2020). These studies indicated that the etiology of PD is not entirely clear and has a complex and multifactorial nature (Olanow and Tatton, 1999; Takahashi and Yamada, 1999; Thomas and Beal, 2007; Guttuso et al., 2019b; O’Callaghan and Miller, 2019; Hasan et al., 2020). Etiological risk factors are considered a combination of age, gender, genetic background, and environmental factors (Carvey et al., 2003; Thomas and Beal, 2007; Pavlou and Outeiro, 2017; Videira and Castro-Caldas, 2018; Guo et al., 2019; Mehra et al., 2019; Delic et al., 2020; Kline et al., 2020). Nevertheless, less than 15% of PD cases have a family history, and most of them are sporadic and seemingly caused by deleterious environmental factors acting synergically with susceptibility genes to affect the striatum activity (Foltynie et al., 2002a, b; Ferrer et al., 2011; Wirdefeldt et al., 2011; Deng et al., 2018; Guo et al., 2019). However, much remains unclear, and effective treatments have yet to be developed based on innovative new strategies (Liu et al., 2010; Campos et al., 2011; Schapira, 2011; Irwin et al., 2016; Wang et al., 2017; Shimohama and Kawamata, 2018; Iarkov et al., 2020). A decline of the flow of information from midbrain dopaminergic neurons to the striatum, limbic, and cortical regions and a deficiency of dopamine (DA) in these structures are central events triggering PD (Alexander, 2004; Cerasa et al., 2016; Anderkova et al., 2017; Galantucci et al., 2017). The decrease of incoming dopaminergic input disrupts complex regulatory mechanisms in the overlying structures (Gale et al., 2008; Schapira and Jenner, 2011; Singh et al., 2017). Deficiency of DA can arise due to the neuronal death or synaptic dysfunction of dopaminergic neurons in the midbrain (Schulz-Schaeffer, 2010, 2015; George et al., 2013). The striatum contains mainly GABAergic medium spiny neurons (MSN) and large aspiny choline interneurons ChIs (Alexander et al., 1986; Conti et al., 2018; Tanimura et al., 2018; Martel and Apicella, 2021). At the cellular level, DA deficiency induces an imbalance of the activity of different MSN populations resulting in motor and behavioral disturbances (Alexander, 2004; Taverna et al., 2008; Tozzi et al., 2011; Gallo, 2019; Iarkov et al., 2020). MSNs expressing the DA receptor 2 (D2R) will decrease their activity, while neurons expressing the DA receptor 1 (D1R) will increase it (Taverna et al., 2008; Tozzi et al., 2011; Gallo, 2019). Alteration of the indirect and direct pathways to globus pallidus internal (GPi)/Substantia nigra pars reticulata (SNpr) impairs the communication of the thalamus with the motor cortex resulting in motor dysfunction (Alexander et al., 1986; Bjorklund and Dunnett, 2007; Rodriguez-Sabate et al., 2021). In other words, an enhanced excitatory output from the subthalamic nucleus (STN) increases the activity of the GP that induces an anomalous inhibitory outflow to the thalamus and brain stem areas (Braak and Braak, 2000; Cerasa et al., 2016; Iarkov et al., 2020; van Nuland et al., 2020). The inhibition of the thalamus affects the thalamocortical communication triggering movement abnormalities characteristic of PD, such as bradykinesia (DeLong, 2000; Poewe et al., 2017; Wichmann, 2018; Reich and Savitt, 2019).

Though PD is a progressive neurodegenerative disease that is mainly considered a clinically dominant movement disorder, it also has noticeable non-motor symptoms such as psychiatric signs of depression, anxiety, and cognitive impairment, some of which may appear even before the motor ones (Hemmerle et al., 2012; Lindqvist et al., 2012; Lohle et al., 2019; Mendonca et al., 2020; Carey et al., 2021; Hussein et al., 2021; Kwon et al., 2021).

Many research groups have investigated the prevalence, sex differences, morphological and functional changes, and biomarkers to predict the progression from cognitive impairment to dementia in PD (Braak et al., 2005; Anang et al., 2017; Hoogland et al., 2017; Ye et al., 2017; Cholerton et al., 2018; Friedman, 2018; Hussain and Camicioli, 2018; Lanskey et al., 2018; Renouf et al., 2018; Zou et al., 2018; Agelink van Rentergem et al., 2019; Berman and Miller-Patterson, 2019; Chondrogiorgi et al., 2019; Chung et al., 2019; Palermo et al., 2019a, b; Yoo et al., 2019; Byeon, 2020).

Almost two decades ago, Braak et al. (2005) found an association between cognitive status and the neuropathologic stages of PD in patients with the sporadic form of the disease. The authors assessed Lewy bodies (LBs) immunoreactive for α-SYN and neuropathological markers for comorbidities such as Alzheimer’s disease (AD) that could be contributing to cognitive decline. The authors divided the patients into groups from marginally impaired cognition to severe dementia according to the Mini-Mental State Examination (MMSE) scores. The results showed that MMSE scores positively and linearly correlated with ascending neuropathologic stages (Braak et al., 2005). Cognitively impaired patients showed higher levels of AD-like neuropathology, including beta-amyloid (Aβ) deposition than cognitively intact patients. MMSE scores did not correlate significantly with disease duration, age at disease onset, or death. The authors concluded that a decrease in MMSE scores between the disease stages 3 to 6 raises the risk of developing dementia during PD progression (Ross et al., 1996; Braak et al., 2005). However, in some patients, cognitive decline develops in the absence of substantial PD-related cortical pathology and, on the contrary, in other patients, extensive cortical neuropathology does not unavoidably lead to cognitive decline and dementia (Green et al., 2002; Braak et al., 2005; Leverenz et al., 2009). Further studies have given more insight into the mechanisms and morphological correlations of cognitive impairment progression to dementia (Aybek et al., 2009; Foster et al., 2013; Aarsland et al., 2017; Lanskey et al., 2018).

On the other hand, other non-motor symptoms, including anxiety and depression, and impulse control disorder, and psychosis, affect many patients, with a prevalence of 50–80%, often appearing at the early stages of the disease is only partially treated by conventional treatments such as L-DOPA and new treatments have been tested (Bonito-Oliva et al., 2014; Titova and Chaudhuri, 2018; Eisinger et al., 2019; Hussein et al., 2021). Experimentally, non-motor symptoms can be induced in mice by bilateral injection of the toxin 6-hydroxydopamine (6-OHDA) in the dorsal striatum. This mouse model of PD-like pathology shows only slight gait modifications, with no horizontal motor activity changes as tested in the open-field test. However, The treated mice showed depressive-like behavior such as increased immobility in the forced swim and tail suspension tests.

Additionally, mice showed anxiety, expressed as a reduced time spent in the open arms in the classic anxiety test elevated plus maze test and increased thigmotaxis in the open-field test. L-DOPA did not decrease depressive- and anxiety-like behaviors. Reboxetine, a noradrenaline reuptake inhibitor, reverted the depressive and anxiogenic effects. However, desipramine used to preserve noradrenaline neurons, when administered before injection of 6-OHDA, did not modify the resultant depressive- and anxiety behaviors. The authors concluded that mood-related disorders were not due to a decrease in noradrenaline (Bonito-Oliva et al., 2014). Last decade studies have indicated the involvement of alteration of the serotoninergic system and its components, such as the serotonin receptors, with the appearance of depression in PD (Ballanger et al., 2012; Bonito-Oliva et al., 2014; Maillet et al., 2016). One of these studies used positron emission tomography (PET) and (18)F (Roselli et al., 2010) MPPF, a selective serotonin 1A receptor antagonist, to investigate whether changes in this receptor activity at the postsynaptic site were involved in the pathophysiology of depression. Compared with non-depressed parkinsonian patients, depressed patients showed a lower tracer uptake in the left hippocampus, the right insula, the left superior temporal cortex, and the orbitofrontal cortex. Compared with controls, non-depressed parkinsonian patients presented a reduced F-18 MPPF uptake bilaterally in the frontal cortex and the right ventral striatum and insula. Compared with controls, F-18 MPPF uptake was decreased in depressed parkinsonian patients in the left dorsal anterior cingulate and orbitofrontal cortices, in the right hippocampal region, and the temporal cortex. The imaging data suggest that serotonin 1A receptor dysfunction in the limbic system may underly depression in patients with PD (Ballanger et al., 2012; Bonito-Oliva et al., 2014; Maillet et al., 2016). The mechanism of action of various neuroprotective strategies to prevent PD is under investigation; however, efficacious new therapeutic approaches still need to be discovered (Guo et al., 2019; Jurado-Coronel et al., 2019; Iarkov et al., 2020).

The Role of Lewy Bodies in PD

The progressive appearance of protein deposits called Lewy bodies often accompanies the loss of dopaminergic neurons in various brain regions (Schulz-Schaeffer, 2010; Mehra et al., 2019). These deposits contain elevated misfolded α-synuclein (α-SYN) oligomers and aggregates, neurofilaments, and ubiquitin inside neurons and glia (Braak et al., 1998; Martin et al., 2012). Although the role of Lewy bodies in the development of PD is still unknown, the neuropathological diagnosis of PD was base on its detection and quantification (Beach et al., 2008, 2009). Intriguingly, not always neurodegeneration of dopaminergic neurons is accompanied by Lewy bodies (Tompkins et al., 1997; Burke and O’Malley, 2013). Patients with mutations in α-SYN present [Parkinson disease (PARK)1, PARK3/4/5] or not present (PARK2 and PARK8) Lewy bodies associated with nigral degeneration (Foltynie et al., 2002b; Duce et al., 2017). Mutations such as PARK1 lead to amino acid changes such as A53T that increase α-SYN aggregation to form oligomers and fibrils (Duce et al., 2017). DA inhibits the transition of the protein oligomers neurotoxic to filaments, a property that may clarify the higher vulnerability of dopaminergic cells to neurodegeneration in PD (Foltynie et al., 2002b). Moreover, neurons in the SN, regardless of whether they contain Lewy bodies or not, present morphological dendritic abnormalities or biochemical changes, indicating that all neurons are involved in the disease process (Patt et al., 1991; Bergeron et al., 1996; Hill, 1996; Devi et al., 2008). Due to its structure, α-SYN can interact with anionic lipids, which leads to conformational changes that facilitate its aggregation into toxic species (Schapira and Jenner, 2011; Bose and Beal, 2016; Shamoto-Nagai et al., 2018; Zeng et al., 2018; Gilmozzi et al., 2020). For instance, the accumulation of mutant forms of α-SYN in the inner mitochondrial membrane disrupts complex I, increasing the production of reactive oxygen species (ROS) and contributing to neuronal apoptosis (Devi et al., 2008). ROS influence cellular self-defenses by promoting the cytoprotective effects of DJ-1 and PTEN-induced putative kinase 1 (PINK1) while inducing Akt dysregulation (Zhao et al., 2017).

Why Are Dopaminergic Neurons in the Midbrain So Vulnerable?

Dopaminergic neurons in the midbrain have unique morphological characteristics that may contribute to their enhanced vulnerability (Carlsson and Fornstedt, 1991; Chung et al., 2005; Alavian et al., 2008; Hegarty et al., 2013). For example, DA neurons have long unmyelinated axons and massive dendrites that branch out into SNpr, with their somas being less than 1% of the total volume of these cells (Iarkov et al., 2020). Due to this morphology, a relatively small number of neurons provide massive dopaminergic innervation of the striatum (Sulzer, 2007). It has been calculated that each neuron in the SN may have up to 150,000 presynaptic terminals in the striatum (Oorschot, 1996; Sulzer and Schmitz, 2007). The normal functioning of such neurons requires highly active axonal transport through microtubules to support metabolic and reparative processes, synaptogenesis, removal of cellular waste, and communication with other brain cells (Prots et al., 2013, 2018; Lu et al., 2014). These cellular process demands high levels of ATP, turning DA neurons in the SN exceptionally susceptible to mitochondrial dysfunction during the development of PD (Horowitz et al., 2011; Venkateshappa et al., 2012; Vanhauwaert and Verstreken, 2015; Course and Wang, 2016; Burbulla et al., 2017).

Molecular Mechanisms Associated With PD

It is reasonable to postulate that an accumulation of risk factors above the repair capacity of DA neurons triggers mitochondrial dysfunction, abnormal accumulation of misfolded proteins, oxidative stress, and tau hyperphosphorylation in the PD brain (Alexander, 2004; Perier and Vila, 2012; Franco-Iborra et al., 2016; Jiang and Dickson, 2018). Tau dysfunction disrupts the potential of the mitochondrial membrane, impairs the activity of respiratory enzymes, resulting in a decreased ATP production and energy supply as well as increased reactive oxygen species (ROS) production (O2–and H2O2) (Bose et al., 2011; Keane et al., 2011; Sutachan et al., 2012). Oxidative stress damages cellular organelles and the DNA, an event that is particularly dangerous for mitochondrial DNA that does not have protective histones and therefore is more vulnerable to ROS damage than nuclear DNA (Dexter and Jenner, 2013). Once started, the disease develops on the principle of positive feedback; oxidative stress can potentiate different risk factors, such as age and unfavorable environmental conditions to induce mutations in both cellular and mitochondrial DNA (Bandy and Davison, 1990). Although mitochondria contain the genetic information to produce proteins, most mitochondrial proteins, including those involved in DNA transcription, translation, and repair, are encoded by nuclear DNA and transported to mitochondria from the cytosol (Lenka et al., 1998; Lee et al., 2005). DNA mutations affecting genes involved in mitochondrial electron transport, glucose utilization, and glucose sensing may correlate with PD occurrence (Blanch et al., 2016; Requejo-Aguilar and Bolanos, 2016; Grunewald et al., 2019). It has been found that 28 sets of genes are linked to PD, likely playing a pathogenic role at the early stages of the disease (Anderson and Becker, 1981; Zheng et al., 2010; Keane et al., 2011). Currently, a more extensive list of genes is associated with the onset of PD, supporting the multifactorial etiology of both familial and sporadic cases of PD (Scott et al., 2017; Lu et al., 2018; Zeng et al., 2018; Kline et al., 2020; Wang et al., 2020b; Allende et al., 2021; Martinez-Banaclocha, 2021).

An early study investigating changes in the binding of the α4β2 nAChR tracer 5- (125)I-A-85380 in PD found a loss of striatal 5-(125)I-A-85380 binding that correlated with the loss of nigrostriatal dopaminergic markers (Pimlott et al., 2004). Similar changes were observed in subjects with dementia with Lewy bodies (DLB) that showed a reduced striatal 5-(125)I-A-85380 binding density, which the authors interpreted as an early degeneration in nigrostriatal inputs. These results suggest the involvement of the nAChRs on PD etiology (Pimlott et al., 2004). In agreement with this idea, multiple epidemiological studies have shown that active smokers have a lower risk of developing PD (Fratiglioni and Wang, 2000; Quik, 2004; Chapman, 2009; Chen et al., 2010; Greenbaum et al., 2013; Gallo et al., 2019; Cheng and Wang, 2020; Kim et al., 2020; Mappin-Kasirer et al., 2020) encouraging the investigation of the potential neuroprotective effects of alkaloids such as nicotine and other nicotinoids from tobacco plants with positive results (Maggio et al., 1998; Linert et al., 1999; Court et al., 2000; Mihailescu and Drucker-Colin, 2000; Quik and Kulak, 2002; Soto-Otero et al., 2002; Quik et al., 2006; Park et al., 2007; Bordia et al., 2008; Huang et al., 2009). This effect has been attributed mainly to nicotine or its metabolites acting on the AChRs (Bordia et al., 2008; Huang et al., 2009). On the other hand, nAChRs are expressed on every cell of the dopaminergic system and exert many neuroprotective effects. For this reason, modulators of the nAChRs may act as preventative drugs against PD deserve more in-depth consideration (Parain et al., 2001, 2003; Soto-Otero et al., 2002; Bordia et al., 2008; O’Leary et al., 2008; Riveles et al., 2008; Hong et al., 2009; Huang et al., 2009, 2011b; Bordia et al., 2010; Quik et al., 2012, 2013a; Barreto et al., 2014; Iarkov et al., 2020).

On the other hand, other authors have attributed these potential positive effects of tobacco consumption in decreasing the risk for PD to the content of lithium in the cigarettes (Guttuso, 2019; Guttuso et al., 2019a, b). These effects have been linked to changes in the activity of beta-Catenin, a transcriptional cofactor that upregulates the expression of canonical Wnt target genes, that it has been found reduced in sporadic PD and cell carrying Leucine-rich repeat serine/threonine-protein kinase (LRPK)2 and beta-glucosidase PD-linked mutations (Marchetti, 2018). Also, smokers’ brains have significantly lower alpha-synuclein levels. Tobacco contains very high lithium levels compared to other plants. Lithium has a broad array of neuroprotective actions, including enhancing autophagy and reducing intracellular alpha-synuclein levels, and is effective in neurotoxin and transgenic preclinical PD models (Guttuso, 2019; Guttuso et al., 2019a, b; Vallee et al., 2021). One of the lithium’s neuroprotective actions is the enhancement of beta-catenin-mediated activity, leading to increased Nurr1 expression through its ability to inhibit glycogen synthase kinase-3 beta (GSK3β) (Zhu et al., 2014; Guttuso, 2019; Guttuso et al., 2019b; Vallee et al., 2021). The authors hypothesized that inhaled lithium from smoking might account for the associated reduced rates of PD, a beneficial effect mediated by the inhibition of GSK3β and activation of beta-catenin, two factors that could be effective therapeutic targets against PD, for neuroprotective drugs, including the ones modulating the α7nAChRs (L’Episcopo et al., 2014; Liu et al., 2017; Guttuso, 2019; Guttuso et al., 2019b; Vallee et al., 2021).

Neurotransmitter Systems in the Striatum Altered by PD

The striatum receives many synaptic inputs from all cortical regions and the thalamus providing excitatory glutamatergic afferents (Aosaki et al., 2010; Ferre et al., 2010; Huang et al., 2011a, b). At the same time, the nigrostriatal pathway delivers modulatory neurotransmitters such as DA, ACh, GABA, nitric oxide, and adenosine (Calabresi et al., 2000a; Morelli et al., 2010; Parent et al., 2011; Tripathy et al., 2015; Sanjari Moghaddam et al., 2017; Lopes et al., 2019). All these neurotransmitter systems modulate the efficacy of the synaptic transmission in the striatum, which processes excitatory glutamatergic signals from cortical and thalamic afferents and modulates signals from dopaminergic neurons of the midbrain, aspiny GABAergic, and cholinergic interneurons (Bolam et al., 2000; Kreitzer and Malenka, 2008; Gerfen and Surmeier, 2011). These signals are received and processed by the dorsal striatum MSN, which make up 90–95% of the striatum neuron population (Tepper et al., 2007). The remaining 5–10% of striatum neurons are interneurons, including the GABA and ACh interneuron (ChI) populations, which are significant regulators of both MSN and striatal afferents (Durieux et al., 2011; Munoz-Manchado et al., 2018). Among them, the most important are ChIs, which closely interact with DA afferents of the midbrain (Kim et al., 2019; Dautan et al., 2020). The glutamatergic, serotonergic, cholinergic, GABAergic, noradrenergic systems are involved in modulating the striatum’s output signals (Calabresi et al., 2000a; Do et al., 2012; Zhai et al., 2019). In addition, opioids, neuropeptides, steroids, and adenosine receptors families are present in the dorsal striatum (Aosaki et al., 2010; Ferre et al., 2010; Huang et al., 2011b; Moreno et al., 2011; Quik et al., 2012, 2013a; Almey et al., 2015; Iarkov et al., 2020). Due to the presence of such a variety of modulators, DA deficiency could be surmounted by modulating these receptors (Quik and McIntosh, 2006; Quik et al., 2007; Livingstone and Wonnacott, 2009; Avena and Rada, 2012; Goldberg et al., 2012; Mathur and Lovinger, 2012; Myslivecek et al., 2017; Ferre and Ciruela, 2019; Ztaou and Amalric, 2019; Liu, 2020).

Interaction of the Cholinergic and Dopaminergic Systems in the Striatum

Both the dopaminergic and cholinergic systems belong to the regulatory systems of the brain, the neurons of which are actively involved in maintaining the body’s homeostasis (Picciotto et al., 2012; Rizzi and Tan, 2017). They have a similar anatomical structure with the neuronal bodies of both systems located in the brain stem, midbrain, and subcortical structures of the forebrain, and they send their axons throughout the forebrain toward the cortex hippocampus, and limbic structures (see Figure 1). Both express several different types of receptors that can generate a wide range of cellular responses (Rizzi and Tan, 2017). It is essential to keep in mind that during the development of PD, the brain loses not only dopaminergic neurons but also cholinergic and serotonergic neurons (Reader and Dewar, 1999; Roselli et al., 2010; Ferrer et al., 2012; Myslivecek, 2021).

FIGURE 1 Cholinergic and Dopaminergic systems. The diagram describes the Cholinergic (brown) and Dopaminergic (blue) systems. There are four primary sources of cholinergic projections in the mammalian brain. These include pedunculopontine nucleus and laterodorsal tegmental nuclei; a set of thalamic nuclei; striatum, where few cholinergic neurons are local interneurons; and the basal forebrain nuclei, which collectively serve as the primary sources of cholinergic projection neurons in the neocortex, hippocampus, and amygdala. SNc-Substantia nigra pars compacta, VTA, ventral tegmental area.

There are four primary sources of cholinergic projections in the mammalian brain: the pedunculopontine (PPN) and laterodorsal tegmental nuclei, the thalamic nuclei, the striatum, where a small number of giant cholinergic neurons play the role of local interneurons, and the basal forebrain nuclei, that collectively serve as crucial sources of cholinergic neurons projecting toward the neocortex, hippocampus, and amygdala (Figure 1; Garcia-Rill, 1986; Charara and Parent, 1994; Bohnen et al., 2011; Stein and Aziz, 2012; Dautan et al., 2014). The PPN can be divided into two subnuclei, the pars compacta (PPNc) and pars dissipatus (PPNd), and it is involved in starting and modulating stereotyped movements, including gait (Garcia-Rill, 1986; Snijders et al., 2016; Dos Santos et al., 2021). Glutamatergic neurons of the PPNd (pars dissipatus) regulates the basal ganglia and spinal cord. In contrast, the cholinergic pars compacta (PPNc) is part of the loop connecting the spinal cord and limbic areas with the basal ganglia and thalamus (Bohnen et al., 2011; French and Muthusamy, 2018; Bertino et al., 2020). Non-bursting cholinergic PPNc neurons are considered key to sustaining steady-state locomotion (Brimblecombe et al., 2018; Sharma et al., 2020; Huerta-Ocampo et al., 2021). Additionally, small cholinergic neurons are present in the reticular formation, the medial habenula, and the cortex (Mesulam et al., 1983, 1992; Terenzi et al., 1992; Ballinger et al., 2016).

The cholinergic neurons in the striatum play one of the most critical roles in developing symptoms in PD, and their stimulation decrease PD symptomatology (Bohnen et al., 2009; Dautan et al., 2014; Kucinski and Sarter, 2015; Osada and Iwasaki, 2017; Chambers et al., 2019; Lieberman et al., 2019). As mentioned above, the striatum contains giant aspiny ChIs, connecting to medium spiny neurons. Although giants ChIs account for only 1–3% of striatal neurons, they have highly dense axonal arbors that overlap with those of dopaminergic neurons projecting from the SNpc (Dautan et al., 2014, 2020; Mallet et al., 2019; Martel and Apicella, 2021). Thus, the high density of striatal cholinergic markers reveals the vital role of the cholinergic neurotransmission in modulating striatal function (Phelps et al., 1985; Calabresi et al., 2000a, b; Mallet et al., 2019; Martel and Apicella, 2021).

Research over the past decade shows that striatal ChIs maintain synaptic plasticity and are involved in memory and other cognitive functions mediated by the posterior striatum, such as attention and motivation (Bennett et al., 2000; Bohnen et al., 2011; Havekes et al., 2011; Deffains and Bergman, 2015). ChIs display a constant spiking activity in the absence of synaptic inputs (Bennett et al., 2000; Goldberg and Reynolds, 2011). Changes in ChI activity occur during associative conditioned learning (Robinson et al., 2011; Jiang et al., 2016). For example, in classical conditioning studies, the temporal pattern of ChIs activity has been investigated. In these experiments, animals learned to associate a conditioned stimulus (CS) (a tone) with an unconditioned stimulus (US) (a food reward) (Wilson and Fadel, 2017; Kellis et al., 2020). The results showed that during conditioning, shortly after the presentation of the CS, ChIs typically responded with a pause in firing that lasted approximately 200 ms. This pause was preceded or followed by an excitatory burst response (Mallet et al., 2019). This evidence supports the view that ChIs are involved in acquiring contextual information during conditioning learning (Aosaki et al., 1994a, b; Apicella, 2017). ChIs modulation with a cholinergic agonist mimicked the electrical oscillations in the striatum of PD brains (McCarthy et al., 2011). Furthermore, Opto-excitation of ChIs in healthy animals resulted in PD-like motor deficits (Kondabolu et al., 2016), while ChIs Opto-inhibition decreased them in PD mice (Maurice et al., 2015). Other scientists have investigated how the temporality of ChIs activity shapes striatal function using optogenetics coupled to the direct infusion of cholinergic modulators in the striatum (Mallet et al., 2019). Overall, this evidence suggests that both ChI and dopaminergic neurons work together to regulate some motor and cognitive functions and represent promising targets for alleviating the symptoms in PD (Iarkov et al., 2020).

The Development of an Imbalance Between Different Systems in the Striatum as the Main Contributing Factor in PD

Dopamine deficiency in the striatum causes an imbalance of activity between two MSN populations, each expressing only one type of receptor (D1R or D2R). Each of both MSN groups has a unique path to the GPi/SNpr neurons. MSNs expressing D1R form a direct pathway, while those expressing D2R form an indirect pathway via the GPe and the subthalamic nucleus (STN) (Alexander, 2004; Tozzi et al., 2011; Lu et al., 2021). DA deficiency causes a decrease in the activity of MSN expressing D1R and increases the activity of neurons expressing D2R, thereby causing motor and cognitive dysfunctions (Alexander, 2004; Tozzi et al., 2011; Wang et al., 2019). The balance between the dopaminergic and cholinergic systems is vital for the correct functioning of the striatum (Aosaki et al., 2010; Lester et al., 2010; Crans and Ciruela, 2021). PD symptoms such as tremor and rigidity are ameliorated by L-DOPA and anticholinergic drugs, suggesting that PD is a hypercholinergic disorder induced by a dysbalance between Dopaminergic and cholinergic systems (Bohnen and Albin, 2011; Tata et al., 2014; McKinley et al., 2019).

Parkinson’s disease develops as an imbalance between dopaminergic inputs and cholinergic interneurons as well as between the serotoninergic and histaminergic systems, increasing the histaminergic tone and decreasing the serotoninergic and dopaminergic activities (Fahn, 1989; Przuntek and Muller, 1999; Aquino-Miranda et al., 2012; Johnston et al., 2019). This hypothesis is coherent because PD symptoms can be successfully relieved by anticholinergics and anti-histamine drugs such as Benadryl (Barbeau, 1962). However, the prescription of anticholinergic drugs stopped due to their undesired side effects, including the impairment of cognitive abilities (Cooper et al., 1992; Herzallah et al., 2010; Crispo et al., 2016). These results suggest that a deterioration of the ascending cholinergic neurons observed post-mortem in PD brains might underly the behavioral deficits in tasks depending on the subcortical frontal cortex. After the work of Alexander and DeLong (Alexander et al., 1986; DeLong, 2000), the concept changed, but now many researchers are again paying attention to it, and, considering that an imbalance between the ChIs activity and DA input signals contributes to the development of PD (Threlfell et al., 2012; Ztaou and Amalric, 2019). Fortunately, over the last decade, results obtained with new research methods have clarified the main aspects of the complex relationship between these two systems, clarifying that ChIs is modulated mainly by dopaminergic neurons located in the SN and the VTA (Threlfell and Cragg, 2011; Gonzales and Smith, 2015).

Direct pathway MSNs are activated by dopaminergic signals via D1R and inhibited by ChIs signals via M4 mAChRs in these cells expressing D1R (Bonsi et al., 2011; Gerfen and Surmeier, 2011; Oldenburg and Ding, 2011). The MSNs forming the indirect pathway are inhibited by inputs from dopaminergic neurons through D2R but activated by inputs coming from ChIs stimulating the M1 mAChRs (expressed in both MSNs expressing D1R and D2R) (Bonsi et al., 2011; Gerfen and Surmeier, 2011; Oldenburg and Ding, 2011; Goldberg et al., 2012; Rizzi and Tan, 2017). Thus, the dopaminergic system of the midbrain and striatal ChIs modulate each other to maintain the functional balance between the direct and indirect pathways, precisely controlling the movement (Liu, 2020). At the same time, dopaminergic control of ACh release depends on dopaminergic neurons on ChIs expressing D2Rs that decrease ACh release (Stoof et al., 1992; Consolo et al., 1993; Yan et al., 1997; Pisani et al., 2000). Only a tiny fraction of ChI expresses D1Rs, which increases ACh release (Damsma et al., 1991; Di Chiara et al., 1994; Steinberg et al., 1998; Acquas and Di Chiara, 1999; Lim et al., 2014; Gonzales and Smith, 2015). On the other hand, the control by the cholinergic system of DA release depends on the activation of presynaptic nAChRs and the modulation by mAChRs (Acquas and Di Chiara, 1999; Aosaki et al., 2010; Goldberg et al., 2012). Thus, the initial view of an antagonistic relationship between these two systems has evolved. New studies have shown an even higher complexity in their mutual influence that depends on an organism’s physiological state (Ztaou and Amalric, 2019; Liu, 2020). The interaction of these two systems in the striatum is perceived instead not as enmity but as a dynamic interplay in a virtual “neurotransmitter dance” (Surmeier and Graybiel, 2012).

The Nicotinic Receptors in the Striatum

In vertebrate species, 17 different subunits of the nAChRs have been identified (α1–10, β1–4, δ, ε, γ) (Millar, 2003; Dineley et al., 2015; Papke and Lindstrom, 2020). The subunits form homo-and heteropentameric receptors, and the different combinations change their specific pharmacological properties (Wu and Lukas, 2011; Dani, 2015). The nAChRs are composed of α4, α6, α7, β2, and β3 subunits, with preferential expression of the α4β2 and α6β2 receptors (Marchi et al., 2002; Millar and Gotti, 2009; Quik and Wonnacott, 2011; Siciliano et al., 2017). Under basal conditions, binding of ligands to the α7nAChR induces a conformational change of the receptor that opens the central channel permitting the influx of sodium and calcium ions and the efflux of potassium ions (Albuquerque et al., 2009). The α7nAChRs are detectable in cortical glutamatergic terminals, potentially directly modulating corticostriatal transmission (Howe et al., 2016). In the striatum, the nAChRs are not expressed in the MSN; however, they are extensively distributed on GABAergic interneurons and dopaminergic and glutamatergic terminals, thereby having the physiological mechanism for a fine-tuned modulation of the striatum (Marshall et al., 1997; Kaiser and Wonnacott, 2000; Howe et al., 2016; Siciliano et al., 2017). Additional studies showed that activation of nAChRs, stimulated the GABAergic interneurons (English et al., 2011; Luo et al., 2013), indirectly affecting the striatal dopaminergic activity (Adermark et al., 2011; Clarke and Adermark, 2015).

What Are the Mechanisms Involved in the Putative Neuroprotective Effects of Tobacco Consumption?

The nAChRs have attracted particular interest among researchers after numerous epidemiological studies have confirmed the low incidence of PD in active smokers (Chen et al., 2010; Gallo et al., 2019). The activation of the cholinergic system is the best target to induce neuroprotection by nicotine-derived compounds in PD (Quik et al., 2011, 2015a, b; Zhang et al., 2013; Bordia et al., 2015; Jurado-Coronel et al., 2019; Iarkov et al., 2020). ACh and other ligands acting on the AChRs stimulate the release of DA in the striatum, reduce neuroinflammation and gliosis, and promote neuronal survival and synaptic plasticity in the brain (Zhou et al., 2003; Quik et al., 2007; Goldberg et al., 2012; Jurado-Coronel et al., 2016; Abudukeyoumu et al., 2019; Bordia and Perez, 2019; Liu, 2020). Distinctively, mAChRs are expressed exclusively in the MSNs (Zhou et al., 2003; Goldberg et al., 2012).

The nAChRs are present in dopaminergic neurons, glutamatergic neurons, cholinergic interneurons (ChIs), and GABAergic interneurons in the striatum (Tanaka et al., 2010; Searles Nielsen et al., 2012; Mappin-Kasirer et al., 2020).

Since tobacco smoke contains nicotine, an agonist of the nAChRs, its protective effect has been related to the activity of nicotine on these receptors (Quik and McIntosh, 2006; Quik et al., 2007, 2009, 2012, 2013a, b; O’Leary et al., 2008; Riveles et al., 2008; Hong et al., 2009; Huang et al., 2009, 2011b; Kyaw et al., 2013; Barreto et al., 2014; Tiwari et al., 2015). In the last decades, new evidence highlights cotinine’s neuroprotective actions, a derivative of nicotine that is a positive modulator of the α7nAChRs (Soto-Otero et al., 2002; Buccafusco and Terry, 2003; Terry et al., 2005; Echeverria and Zeitlin, 2012; Barreto et al., 2014; Gao et al., 2014; Boiangiu et al., 2020; Iarkov et al., 2020). Cotinine, acting on the α7nAChRs, stimulates mechanisms of neuroprotection acting on glial cells (Morioka et al., 2018; Oliveros-Matus et al., 2020). The actual evidence suggests that activated microglia (M1 microglia) contributes to PD development (Bayarsaikhan et al., 2015; Saitgareeva et al., 2020). Thus, decreasing microglial activation could be an excellent therapeutic strategy for preventing or treating PD.

α7nAChRs are unique targets to diminish the synthesis of proinflammatory molecules and neuroinflammation due to their ability to inhibit microglial activation (Kim et al., 2015; Lee et al., 2015). Also, in microglia, the glutamate transporter (GLAST) is upregulated by α7nAChRs stimulation through the activation of both inositol triphosphate-Ca2+/calmodulin-dependent protein kinase II (CaMKII) and fibroblast growth factor-2 (FGF2) pathways (Morioka et al., 2014). The activation of microglial α7nAChRs is neuroprotective by inhibiting the expression of proinflammatory molecules and preventing excitotoxicity by promoting glutamate clearance (Morioka et al., 2018).

The Neuroprotective Role of the nAChRs

The cholinergic system plays a vital role in controlling the release of neurotransmitters, decreasing neuroinflammation, promoting synaptic plasticity, and neuronal survival in the brain (Van Beek and Claassen, 2011; Hampel et al., 2018). In addition, the cholinergic system modulates both innate and adaptive immune responses (Bosmans et al., 2017; Halder and Lal, 2021; Pohanka, 2021). The cholinergic system affects immune cell proliferation, T-helper differentiation, antigen presentation, and cytokine production (Fujii et al., 2017; Halder and Lal, 2021; Lu and Wu, 2021). In agreement with these functions, the α7nAChRs are expressed in basophils, dendritic cells, macrophages, mast cells, and T and B lymphocytes (Sato et al., 1999; Skok et al., 2003; Sudheer et al., 2006; de Jonge and Ulloa, 2007; Mashimo et al., 2020). In addition, in neurons, presynaptic nAChRs modulate neurotransmitter release, while postsynaptic nAChRs increase neuronal firing rate, promoting long-term potentiation, considered a cellular mechanism of memory formation (Wayner et al., 1996; Fujii et al., 1999; Chen et al., 2006; Huang et al., 2008; Albuquerque et al., 2009; Kroker et al., 2011; Srivareerat et al., 2011; Nees, 2015; Echeverria et al., 2016b).

Epidemiological studies have shown a lower rate of development of PD in people who use tobacco products, suggesting that one or more tobacco-derived compounds may have neuroprotective effects (Fratiglioni and Wang, 2000; Parain et al., 2003; Hong et al., 2009). Various studies have shown that nicotine reduces the damage of cultured dopaminergic neurons (Riveles et al., 2008; Toulorge et al., 2011; Getachew et al., 2019). Other studies have shown that nicotine and its major metabolite, cotinine, have neuroprotective effects against 6-hydroxydopamine (6-OHDA) toxicity in cultured SH-SY5Y neuroblastoma cells expressing nAChRs (Pogocki et al., 2007; Riveles et al., 2008). Nicotine also showed neuroprotective effects in animal models of PD when administered before nigrostriatal damage occurs (Linert et al., 1999; Salminen et al., 1999; Huang et al., 2009; Quik et al., 2009, 2015a). The neuroprotective effects of other nAChR modulators have also been investigated with promising results (Pogocki et al., 2007; Tiwari et al., 2013; Jurado-Coronel et al., 2019).

The Nicotinic Receptors and Neuronal Survival in the PD Brain

Numerous studies in this area have shown that these pathways promote neuronal survival, proliferation, and neurite growth as well as neurotransmitter release in the brain and other tissues (Eneroth et al., 1977; Fuxe et al., 1979; Aizenman et al., 1991; Sastry, 1995; Parain et al., 2001; Buccafusco and Terry, 2003; Koh et al., 2003; de Aguiar et al., 2013; Gao et al., 2014; Tiwari et al., 2015; Majdi et al., 2018).

The two main subtypes of nAChRs are the heteropentameric α4β2, α3β2, α7β2 receptors, and homopentameric α7 receptor, all of which are channels with high permeability to Ca2+ (Akaike and Izumi, 2018). An increase in the intracellular Ca2+ activates critical signaling pathways, linking input signals from the extracellular environment to a cellular response to maintain homeostasis (Gotti et al., 2009; Wang et al., 2012). Some studies have shown that activation of the nicotinic receptors can be neuroprotective by activating signaling pathways stimulated by Ca2+ (Kihara et al., 2001; Dajas-Bailador and Wonnacott, 2004; Rehani et al., 2008; Shimohama and Kawamata, 2018; Takahashi, 2020). For example, nicotine induces neuroprotection throughout the α7- and α4β2 receptors that, when activated, stimulate the expression of pro-survival genes that inhibit apoptosis and support synaptic function (Mudo et al., 2007; Buckingham et al., 2009; Shimohama and Kawamata, 2018; Papke and Lindstrom, 2020). For example, the increase in Ca2+ ion levels induced by ligands of the α7nAChRs activates the phosphatidylinositol-3-kinase (PI3K) signaling pathway (Kihara et al., 2001; Dajas-Bailador and Wonnacott, 2004; Rehani et al., 2008; Shimohama and Kawamata, 2018). For instance, downstream of the α7nAChR the protein kinase Fyn, a member of the Src family, stimulates the PI3K (Gergalova et al., 2014). PI3K phosphorylates Akt, which activates by phosphorylation the transcription factor cAMP response element-binding protein (CREB) (Leinninger et al., 2004; Wang et al., 2020a; Liu et al., 2021). This transcription, in turn, increases the expression of the cell survival factor Bcl-2 (Rehani et al., 2008). Also, Akt inhibits the pro-apoptotic factor GSK3β and, therefore, the phosphorylation of the microtubule-associated protein Tau (Rajmohan and Reddy, 2017; Sayas and Avila, 2021). These actions are relevant to preventing dementia because hyperphosphorylated Tau inhibits axonal transport and induces energy deficits in the brain leading to oxidative stress, synaptic deficits, and neuronal cell death (Perez et al., 2018; Compta and Revesz, 2021; Koziorowski et al., 2021). Coherent with this idea, the positive modulation of the α7nAChR by cotinine is neuroprotective against amyloid-β peptide (Aβ) toxicity in vivo, inhibiting GSK3β-mediated Tau phosphorylation, and activating the transcription factor CREB (required for long-term memory storage), improved memory abilities in mouse models of AD (Echeverria et al., 2011; Echeverria and Zeitlin, 2012; Patel et al., 2014; Grizzell and Echeverria, 2015; Grizzell et al., 2017). Other mechanisms of nAChR-mediated neuroprotection include activating the extracellular signal-regulated protein kinase/mitogen-activated protein kinase (ERK/MAPK) pathway (Grizzell and Echeverria, 2015). The α7nAChRs activate neuroprotective factors stimulated by Ca2+, including the protein kinase C (PKC) and the Ca2+/calmodulin-dependent protein kinase (CaMK), both of which activate CREB (Kawamata and Shimohama, 2011; Kawamata et al., 2011, 2012; Sutachan et al., 2012; Albert-Gasco et al., 2020).

Evidence obtained using agents inducing PD-like pathologies such as Rotenone, 6-OHDA, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), enlightened potential mechanisms of nAChRs-mediated neuroprotection (Kawamata et al., 2011). These mechanisms involve activating the signal transducer and activator of transcription (STAT)1/3/5, and the Fyn/PI3K/Akt/Bcl2, Janus kinase 2 (JAK2)/PI3K/Akt (Bharadwaj et al., 2020). Besides, the stimulation of the α4β2 and α7nAChRs triggers other neuroprotective signaling cascades without the direct involvement of the PI3K system, such as the ERK/MAPK and JAK2/STAT3 pathways, PKC/Raf/MEK/ERK/STAT3, and Ras-Raf-ERK signaling pathways (Figure 2; Buckingham et al., 2009; Zdanowski et al., 2015).

FIGURE 2 Scheme depicting different pro-survival signaling pathways activated by the nAChRs. Nicotine-induced neuroprotection is mediated by receptors, primarily through the α7 and α4β2 receptors. Also, the nAChRs can activate intracellular pathways that enhance the expression of pro-survival proteins that inhibit apoptosis. From them, Janus kinase 2 (JAK2), Fyn, protein kinase C (PKC), and calcium-calmodulin kinase (CaMK) are crucial protein factors triggering the activation of the extracellular signal-regulated protein kinase (ERK), JAK2/signal transducer, and activator of transcription 3 (STAT3), and phosphatidylinositol 3-kinase (PI3K)-Akt pathways. In turn, these pathways enhance the expression of antiapoptotic factors such as Bcl-2.

The α7nAChRs also stimulate the expression and activity of various growth factors and their receptors, such as the vascular endothelial factor (VEGF) and the VEGF receptor 2 (VEGFR2), the platelet-derived growth factor (PDGF) and the PDGF receptor (PDGFR), and the epidermal growth factor receptor (EGFR) (Pillai and Chellappan, 2012). EGFR activates the Akt pathway and its downstream effectors, X-linked inhibitor of apoptosis protein-survivin and the nuclear factor kappa B (NFκB) (Zdanowski et al., 2015). In general, the nAChRs can activate neuroprotective signaling cascades in neurons, astroglia, and microglia to promote cell survival, synaptic plasticity and maintain brain homeostasis (Picciotto et al., 2000; Echeverria and Zeitlin, 2012; Kawamata et al., 2012). For example α7nAChRs upregulate the transcription factors hypoxia-inducible factor-1 (HIF-1), GATA-3, NFκB, and signal transducer and activator of transcription (STAT) 1 (Picciotto et al., 2000; Echeverria and Zeitlin, 2012; Kawamata et al., 2012; Pillai and Chellappan, 2012; Echeverria et al., 2016a, b).

The Muscarinic Receptors in the Striatum

In the striatum, every type of neuron expresses different subtypes of both mAChR and nAChRs (Threlfell et al., 2010; Lim et al., 2014). The mAChRs are metabotropic receptors that indirectly control the activity of membrane ion channels through heterotrimeric G-proteins (Kruse et al., 2014; Roth, 2019). These G-proteins are composed of Gα and Gβg subunits classified according to the type ofα subunit, which determines their association to specific G-protein coupled receptors (GPCR) (Huang and Thathiah, 2015; Roth, 2019).

In the CNS, the mAChRs are categorized into five subtypes groups (M1 to M5) (Lim et al., 2014; Mallet et al., 2019). These receptors show significant differences in expression M1 > M2 > M4 > M3 and M5 (Zhou et al., 2003; Graef et al., 2011).

A study using atropine to inhibit M2 and M3 mAChRs present on the glutamatergic terminals revealed a small but significant increase in corticostriatal transmission, suggesting the existence of tonic cholinergic presynaptic inhibition of this excitatory afferents inputs (Pakhotin and Bracci, 2007; Mallet et al., 2019). At different, the M1 mAChR blocker pirenzepine decreased corticostriatal transmission (Tozzi et al., 2011).

In PD, anti-muscarinic receptor drugs were the first symptomatic PD treatment before discovering L-DOPA (Fahn, 1989). mAChR antagonists were used as early treatments and are still under use in PD (Langmead et al., 2008a, b; Thomas et al., 2009). The muscarinic antagonists decrease the hyperactivity of ChIs and corticostriatal glutamatergic neurotransmission after nigrostriatal denervation (Lim et al., 2014). However, while they provide some benefits, these drugs are not without side effects, including cognitive impairment (Drachman and Leavitt, 1974; Yamamoto et al., 2011). Therefore, there is a need for more selective cholinergic modulators with improved therapeutic properties. In addition, therapies with more selective modulators of the cholinergic receptors may permit more target specificity and improved pharmacokinetics compared to ACh.

The Muscarinic AChRs Signaling and Their Role in Maintaining Brain Homeostasis

The M1, M3, and M5 mAChRs are associated with G-proteins’ Gq/11 subfamily (Sil’kis, 2003; Tobin and Budd, 2003; Santiago and Abrol, 2019). When activated by these receptors, Gq interchanges GTP for GDP and dissociates in their constituent subunits that become free to activate downstream effectors such as the phospholipase C (PLC) (Falkenburger et al., 2010). PLC activity results in the release of inositol-triphosphate 3 (IP3) and diacylglycerol (DG) (Berridge, 2016). IP3 binds to the IP3R in the endoplasmic reticulum (ER), triggering the release of Ca2+ from intracellular stores, and DG stimulates the PKC (Rehman and Dimri, 2020).

The activation of M2 and M4 receptors activates the Gi/o subfamily of G proteins, increasing the opening time of potassium channels and decreasing cAMP production (Santiago and Abrol, 2019). Since this second messenger activates the pro-survival PKA/CREB pathway, this decrease inhibits cell survival and synaptic plasticity in the brain (Resende and Adhikari, 2009). The M2 mAChRs also weakly bind to Gs and Gq, acting as a negative autoreceptor leading to decreased ACh release (Quirion et al., 1990; Wess et al., 2007; Santiago and Abrol, 2019).

On the other hand, the activation of the M1 mAChRs increases the non-amyloidogenic processing of the amyloid precursor protein (APP) to generate sAPPα, a proteolytic product that promotes neuroprotection by stimulating neuritogenesis, neurogenesis, synaptic plasticity, and memory formation while reducing Aβ and Tau pathology in the brain (Deng et al., 2015; Habib et al., 2017).

Some drugs, including non-steroidal anti-inflammatory compounds, have neuroprotective effects by shaping APP processing (Avramovich et al., 2002; Yogev-Falach et al., 2003; Kalaitzakis et al., 2008; Miklossy et al., 2008; Shimohama and Kawamata, 2018). Also, other kinases such as PKC and ERK1/2 stimulate the non-amyloidogenic processing of APP by α-secretase (Wang et al., 2016; Zhang et al., 2019).

Also, M1 mAChR activation upregulates the expression of β-secretase 1 (BACE1) through a mechanism involving the activation of MEK/ERK, by a mechanism prevented by M2 mAChRs activation (Zuchner et al., 2004). Besides, the stimulation of M1 mAChRs counteracted the Aβ-induced inhibition of Wnt signaling by GSK3β, resulting in the stabilization of β-catenin and increased expression of survival genes (Farias et al., 2004; Jiang et al., 2014b; Wysocka et al., 2020). Additionally, the M1 mAChRs, by inhibiting the tau kinase GSK3β also prevented tau hyperphosphorylation and toxicity (Jiang et al., 2014b). Figure 3 represents a possible mAChR signaling mechanism that protects brain cells from mitochondrial dysfunction, caspase activation, oxidative stress, and DNA damage in PD.

FIGURE 3 Neuroprotective signaling pathways stimulated by the mAChRs. M1, M3, and M5 mAChRs are associated with the Gq/11 subfamily of G proteins, which are responsible for the increase of cytosolic Ca2+, activation of phospholipase C (PLC) and protein kinase C (PKC), which leads to the production of signaling molecules inositol triphosphate (IP3) and diacylglycerol (DAG). Acetylcholine (ACh) activation of the M2 and M4 receptors, which are associated with the Gi/o subfamily of G proteins, increases the opening time of potassium channels and decreases the production of adenosine-3′,5′-cyclic monophosphate (cAMP). Besides, the stimulation of the M1 mAChRs by agonists or ACh increases the production of sAPPα and decreases the production of amyloid Aβ peptide. Protein kinase C (PKC) and the extracellular signal-regulated protein kinase (ERK)1/2 are involved in this process by activating α-secretases. The activation of the M1 mAChRs counteracts Aβ-induced neurotoxicity via the Wnt signaling pathway, as Aβ inhibits this pathway through the destabilization of β-catenin. In contrast, stimulation of M1 mAChR inactivates glycogen synthase kinase 3 (GSK3β) via PKC activation, thus stabilizing β-catenin and inducing the expression of the Wnt-targeting and cyclin-D1 genes for neuronal survival.

In agreement with this effect, cell studies indicate that Wnt/β-catenin pathway inhibition mediates manganese-induced neurotoxicity (Jiang et al., 2014a). In AD, increased levels of aggregated forms of Aβ seem to interfere with the function of M1 mAChRs by uncoupling the receptor-G protein complex (Janickova et al., 2013).

On the other hand, the cellular localization of these cholinergic receptors also may play a key role in their function and cellular effects (Anisuzzaman et al., 2013; Uwada et al., 2014; Uspenska et al., 2017; Jong et al., 2018; Muramatsu et al., 2018). Although most cholinergic receptors are located in the plasma membrane to convert extracellular signals into intracellular ones, several studies have reported nAChRs in other neuronal organelles like mitochondria (Skok and Lykhmus, 2016). The current evidence suggests that intracellular α7β2 receptors mainly stimulate the PI3K/Akt pathway, while α3β2 and α4β2 receptors inhibit Akt signaling and Ca2+/calmodulin-dependent pathways, consequently promoting mitochondrial apoptosis (Gergalova et al., 2014; Lykhmus et al., 2014; Muramatsu et al., 2018). New studies indicate that the mAChRs, the cannabinoid receptor, and the metabotropic glutamate receptor 5 (mGluR5) also localize intracellularly in the membranes of various organelles (Jong et al., 2018). In these intracellular locations, they can transmit signals from structures such as endosomes, Golgi apparatus, endoplasmic reticulum, mitochondria, and nucleus (Boivin et al., 2008; Jong et al., 2009; Benard et al., 2012; Gergalova et al., 2014; Lykhmus et al., 2014). Recent studies have shown that approximately half of the M1 mAChRs are in the intracellular part of the membrane in neuronal cells (Anisuzzaman et al., 2013; Uwada et al., 2014). Expression studies using immunohistochemistry methods indicated that the mAChRs could also localize in the Golgi apparatus (Muramatsu et al., 2018). Interestingly, the intracellular localization of the mAChRs requires a C-terminal tryptophan motif that is only present in the M1 subtype. The M1 mAChRs are also present in postsynaptic neurons (Anisuzzaman et al., 2013; Morishima et al., 2013; Uwada et al., 2014; Muramatsu et al., 2018). Figure 4 shows a simplified schematic view of the plasma membrane and intracellular M1 mAChRs in the pre-and postsynaptic neurons, their predicted signal transduction pathways, and the elicited physiological responses. Studies with the GABAA receptor’s competitive antagonist bicuculline suggested that M3 and M4 receptors modulate DA release via facilitation or inhibition of striatal GABA release.

FIGURE 4 Simplified diagram of the AChRs signal transduction pathways in the pre-and post-synaptic sites. In brain cells, intracellular AChRs – both mAChRs and nAChRs are located on both the surface of the plasma membrane and intracellular membranes of various organelles, such as endosomes, Golgi apparatus, endoplasmic reticulum, mitochondria, and nuclear membranes. The choline transporter-like protein1 (CHT1) uptake choline at the presynaptic, and the acetylcholine (ACh) transporter (AChT) uptake ACh at the post-synaptic site. The entrance of calcium throughout the nAChRs stimulates signaling factors, such as the enzymes phosphatidylinositol 3-kinase (PI3K)/extracellular signal-regulated protein kinase (ERK)1/2/signal transducer and activator of transcription 3 (STAT3). These factors prevent apoptosis and stimulate the expression of prosurvival genes, The signaling cascades elicited by the mAChRs stimulate the release of calcium from intracellular stores via the activation of PLC that generates the Inositol trisphosphate (IP3) that activates the IP3 receptors (IP3Rs) and the second messenger diacylglycerol (DAG) that stimulates the protein kinase C (PKC)/Raf/ERK pathway.

Effect of Cotinine Preventing Amyloid-β Peptides Accumulation and Promoting Synaptic Plasticity in the Brain

Despite their structural similarities, nicotine, and cotinine, differ in their mechanism of action, properties, behavioral effects, and toxicity profile (nicotine is one hundred times more toxic than cotinine) (Buccafusco and Terry, 2003; Grizzell and Echeverria, 2015; Majdi et al., 2018). The last decade of research has shown that cotinine has unique pharmacokinetic and pharmacodynamic properties, acting as a very weak nAChR agonist but a positive modulator of the α7nAChRs (Moran, 2012; Grizzell et al., 2014; Sadigh-Eteghad et al., 2020). Different from nicotine, cotinine is safe and does not elicit addictive behaviors in mammals, including humans (Yim and Hee, 1995; Hatsukami et al., 1997; Vainio et al., 1998; Zevin et al., 2000; Echeverria and Zeitlin, 2012; Thomopoulos et al., 2013). Cotinine has shown to protect astrocytes from the toxic effects of chronic and acute stress in vivo (Alvarez-Ricartes et al., 2018; Mendoza et al., 2018; Oliveros-Matus et al., 2020) and to prevent the loss of presynaptic proteins such as synaptophysin in the PFC and hippocampus of mice subjected to chronic stress (Grizzell et al., 2014; Grizzell and Echeverria, 2015). In addition, cotinine has shown to reduce the activation of macrophages (Rehani et al., 2008) and be neuroprotective, reducing plaque deposition, tau hyperphosphorylation, and cognitive impairment while increasing the expression of the postsynaptic density protein 95 (PSD95) in transgenic AD mice overexpressing human Aβ peptides (Terry et al., 2005, 2012, 2015; Echeverria et al., 2011; Echeverria and Zeitlin, 2012; Patel et al., 2014; Grizzell et al., 2017).

In addition, there is evidence suggesting that the activation of the nicotinic receptors by cotinine modulates the stoichiometry and expression of the nAChRs (Lester et al., 2009). A study using neuronal cells and Xenopus oocytes expressing nAChRs (Terry et al., 2015) showed that, like nicotine, cotinine increased the expression of α4β2 receptors on the plasma membrane and induced a change in the intracellular distribution of these receptors. Furthermore, cotinine altered the assembly of α4β2 receptors to favor the assembly of (α4)2(β2)3 receptor’s stoichiometry that has higher sensitivity to the agonists than (α4)3(β2)2 stoichiometry (Srinivasan et al., 2011). Cotinine also decreased the expression of the α6β2β3 receptors (Moran, 2012). In contrast, cotinine did not change the trafficking or expression of α6β2, α4β2α5, or α3β4 receptors (Fox et al., 2015). A previous study compared ACh alone or plus cotinine on the channel activity of the α7 nAChR. The results revealed an enhanced channel activity induced by ACh plus cotinine than the receptors treated with ACh alone (Terry et al., 2015). They also found that exposure to cotinine for 2 days, at doses found in heavy smokers, induced a moderate down-regulation of α4β2 receptors expressed in Xenopus laevis oocyte (Terry et al., 2015). A contemporary study, using a combination of fluorescence imaging and single-molecule measurements, showed evidence that cotinine at concentrations higher than 5 μM did not increase the receptor expression on the plasma membrane, but lower concentrations of cotinine change both the assembly and trafficking of the nAChRs (Fox et al., 2015). No doubt that these changes affect their affinity for the ligands and their function in the brain. New studies are required to define these differences in more detail.

Many studies have shown that modulators of the nicotinic receptors such as nicotine and Cotinine control the release of neurotransmitters such as serotonin (O’Leary et al., 2008) and DA (Fuxe et al., 1986) in the brain (Fuxe et al., 1979), GABA and glutamate (Yan et al., 2019) affecting brain connectivity and its function.

Predicting the Development of PD Dementia

In addition to motor deficits, PD presents with non-motor alterations, including cognitive decline, symptoms of depression, abnormal autonomic nervous system function (dysautonomia), and psychosis (Hemmerle et al., 2012; Lindqvist et al., 2012; Grover et al., 2015; Maillet et al., 2016; Samudra et al., 2016; Hussein et al., 2021). Although memory and language dysfunctions are less evident than the observed in AD, PDD is 600% higher than in the general population. One prospective 8-year study found a cumulative prevalence of dementia of 78% among PD patients (Emre et al., 2007). In another study to a 5-year prospective study in more than 400 patients with PD, the risk factors for dementia included older age, longer disease duration, later age-at-onset, and higher daily levodopa (l-dopa) dosage (Aarsland et al., 2003). PDD, like AD, shows cognitive symptoms such as a diminution of attention and executive and visuospatial abilities (Fitts et al., 2015; Ho et al., 2020; Hussein et al., 2021). PDD seems to result from a combination of AD-like, cortical Lewy-bodies and vascular pathology induced by high homocysteine level (hyperhomocysteinemia), and dysautonomia with abnormal blood pressure (BP), breathing and digestive problems, and loss of bladder control (Zoccolella et al., 2006; Byeon, 2020; Kwon et al., 2021).

In PD, it is challenging to assess the progression to dementia. Structural changes in the PD brain could predict motor and cognitive outcomes (Byeon, 2020; Chung et al., 2021; Owens-Walton et al., 2021; Shin et al., 2021). For example, previous studies have found a correlation between cortical thinning and PD dementia (PDD) (Chung et al., 2021). The methodological advances in structural and functional brain analysis could permit the prediction of PDD development in clinical settings (Oldan et al., 2021; Owens-Walton et al., 2021; Shin et al., 2021). A recent retrospective study explored whether the assessment of cortical thickness by MRI combined with other clinical symptoms using a machine learning-based model could predict the transition from mild cognitive impairment (MCI) to dementia in PD. The study involved patients diagnosed with PD and MCI and evaluated with MRI for 8 years. Features were chosen from clinical and cortical thickness variables to support vector machine models (Shin et al., 2021). From all participants, 42 patients advanced to PDD (converters), and 75 patients did not advance to PDD (non-converters). Models exhibited fair to good predictive outcomes; however, their performances increased when models included both clinical and structural variables (AUC range, 0.80–0.88). In pair-wise comparisons, models trained with both variables obtained better achievements. The authors concluded that Cortical thickness from MRI could help forecast transition from MCI to dementia in PD with improved accuracy when combined with other clinical variables (Shin et al., 2021).

Another recent study used structural and functional MRI to elucidate pathophysiological mechanisms associated with cognitive impairment and dementia in PD (Owens-Walton et al., 2021). They specifically investigated resting-state functional connectivity and morphology of the caudate nucleus, putamen, and thalamus, in PD brains. The results revealed enhanced functional connectivity of the dorsal caudate, anterior putamen, and mediodorsal thalamic subdivisions with the frontal lobe and lower functional connectivity of the dorsal caudate with posterior cortical, and cerebellar regions. Compared to cognitively unimpaired subjects, those with mild cognitive impairment (n = 22) demonstrated reduced functional connectivity of the mediodorsal thalamus with the paracingulate cortex while also demonstrating increased functional connectivity of the mediodorsal thalamus with the posterior cingulate cortex, compared to subjects with dementia (n = 17). The patients with PDD showed a significant reduction in volume in those regions compared to controls or PD participants without dementia. The authors concluded that abnormalities in the functional connectivity of the basal ganglia-thalamocortical circuits, mainly between the mediodorsal thalamus with the cingulate regions, are involved in the appearance of dementia in PD (Owens-Walton et al., 2021). Changes in connectivity can predict the severity of the disease, with the pattern of connectivity considered a form to predict the response to L-DOPA and cognitive status in the PD patients (Amboni et al., 2015; Akram et al., 2017; Anderkova et al., 2017; Chung et al., 2021).

Conclusion

The cholinergic system has a powerful influence over the striatum function by controlling the dopaminergic activity and promoting the survival of neurons to mitochondrial dysfunction, oxidative stress, and neuroinflammation. The dopamine-centric view of PD has failed to control the pathology, and new and more integral approaches considering the disbalance of other neurotransmitters such as serotonin, histamine, and ACh need to be addressed to prevent the loss of dopaminergic neurons in PD. Cotinine positively modulates the nAChRs, and affects the release of serotonin, DA, GABA and glutamate receptors in the brain facilitating brain connectivity and function (Stone, 2021). Based on this evidence, it is reasonable to postulate that cotinine could be a critical factor delaying cognitive impairment in PD or PDD in tobacco users. Further preclinical and clinical studies are required to fully unmask the potential beneficial effects of cotinine in PD.

Author Contributions

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Funding

This work was supported by the National Commission for Scientific and Technological Research in Chile (ANID) (grant FONDECYT 1190264) and the Universidad San Sebastián, Chile.

The result of this work was supported by the resources and facilities from the Universidad San Sebastián (Chile). The contents do not necessarily represent the views of the Department of Veterans Affairs or the United States Government.

Abbreviations

MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

6-OHDA 6-hydroxydopamine

ATP adenosine 5′-triphosphate

α-SYN Alpha synuclein

Aβ Amyloid beta peptide

APP Aβ precursor protein

AChEI acetylcholinesterase inhibitors

AD Alzheimer’s disease

BDNF brain-derived neurotrophic factor

CREB cAMP response element-binding protein

ChI cholinergic interneurons

COX-2 cyclooxygenase 2

DA dopamine

D1R dopamine receptor 1

D2R dopamine receptor

EGFR epidermal growth factor receptor

ERK extracellular signal-regulated protein kinase

GFAP glial fibrillar acidic protein

GSK3 βglycogen synthase kinase 3β

GPi Globus pallidus internal

GST glutathione S-transferase activity

HIF-1 hypoxia-inducible factor-1

IL Interleukin

JAK2 Janus kinase 2

MRI Magnetic resonance imaging

MCI Mild cognitive impairment

MAOIs monoamine oxidase inhibitors

NF κ B neurotrophic factor kappa B

nAChRs nicotinic acetylcholine receptors

mAChRs muscarinic acetylcholine receptors

NOS nitric oxide synthase

NMDA N-methyl -D-aspartate

PAM positive allosteric modulator

PD Parkinson’s disease

PARK2 Parkinson disease-2

PARK8 Parkinson disease-8

PDD Parkinson’s disease dementia

PDGF platelet-derived growth factor

PDGFR PDGF receptor

PI3K phosphatidylinositol 3-kinase

Akt Protein kinase B

PPN pedunculopontine

PPNd PPN pars dissipatus

PPNpc PPN pars compacta

PSD95 postsynaptic density protein 95

STAT signal transducer and activator of transcription

SN substantia nigra

SNpc SN pars compacta

STN subthalamic nucleus

TNF tumor necrosis factor

VEGF vascular endothelial growth factor

VEGFR vascular endothelial growth factor receptor

VTA ventral tegmental area.
==== Refs
References

Aarsland D. Andersen K. Larsen J. P. Lolk A. Kragh-Sorensen P. (2003). Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60 387–392. 10.1001/archneur.60.3.387 12633150
Aarsland D. Creese B. Politis M. Chaudhuri K. R. Ffytche D. H. Weintraub D. (2017). Cognitive decline in Parkinson disease. Nat. Rev. Neurol. 13 217–231. 10.1038/nrneurol.2017.27 28257128
Abudukeyoumu N. Hernandez-Flores T. Garcia-Munoz M. Arbuthnott G. W. (2019). Cholinergic modulation of striatal microcircuits. Eur. J. Neurosci. 49 604–622. 10.1111/ejn.13949 29797362
Acquas E. Di Chiara G. (1999). Dopamine D(1) receptor-mediated control of striatal acetylcholine release by endogenous dopamine. Eur. J. Pharmacol. 383 121–127. 10.1016/s0014-2999(99)00570-1 10585525
Adermark L. Clarke R. B. Soderpalm B. Ericson M. (2011). Ethanol-induced modulation of synaptic output from the dorsolateral striatum in rat is regulated by cholinergic interneurons. Neurochem. Int. 58 693–699. 10.1016/j.neuint.2011.02.009 21333709
Agelink van Rentergem J. A. de Vent N. R. Huizenga H. M. Murre J. M. J. Consortium A. Schmand B. A. (2019). Predicting progression to parkinson’s disease dementia using multivariate normative comparisons. J. Int. Neuropsychol. Soc. 25 678–687. 10.1017/S1355617719000298 31084642
Aizenman E. Tang L. H. Reynolds I. J. (1991). Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551 355–357.1833030
Akaike A. Izumi Y. (2018). “Overview,” in Nicotinic Acetylcholine Receptor Signaling in Neuroprotection, eds Akaike A. Shimohama S. Misu Y. (Singapore: Springer), 1–15.
Akram H. Wu C. Hyam J. Foltynie T. Limousin P. De Vita E. (2017). l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson’s disease. Mov. Disord. 32 874–883. 10.1002/mds.27017 28597560
Alavian K. N. Scholz C. Simon H. H. (2008). Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death. Mov. Disord. 23 319–328. 10.1002/mds.21640 18044702
Albert-Gasco H. Ros-Bernal F. Castillo-Gomez E. Olucha-Bordonau F. E. (2020). MAP/ERK Signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int. J. Mol. Sci. 21 :21124471 . 10.3390/ijms21124471 32586047
Albuquerque E. X. Pereira E. F. Alkondon M. Rogers S. W. (2009). Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev. 89 73–120. 10.1152/physrev.00015.2008 19126755
Alexander G. E. (2004). Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues Clin. Neurosci. 6 259–280.22033559
Alexander G. E. DeLong M. R. Strick P. L. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9 357–381.3085570
Allende M. L. Zhu H. Kono M. Hoachlander-Hobby L. E. Huso V. L. Proia R. L. (2021). Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease. Cell Signal 78 :109879 . 10.1016/j.cellsig.2020.109879 33296739
Almey A. Milner T. A. Brake W. G. (2015). Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. Horm. Behav. 74 125–138. 10.1016/j.yhbeh.2015.06.010 26122294
Alvarez-Ricartes N. Oliveros-Matus P. Mendoza C. Perez-Urrutia N. Echeverria F. Iarkov A. (2018). Intranasal cotinine plus krill oil facilitates fear extinction, decreases depressive-like behavior, and increases hippocampal calcineurin a levels in mice. Mole. Neurobiol. 55 7961–7961. 10.1007/s12035-018-1095-8 29744810
Amboni M. Tessitore A. Esposito F. Santangelo G. Picillo M. Vitale C. (2015). Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease. J. Neurol. 262 425–434. 10.1007/s00415-014-7591-5 25428532
Anang J. B. Nomura T. Romenets S. R. Nakashima K. Gagnon J. F. Postuma R. B. (2017). Dementia predictors in parkinson disease: a validation study. J. Parkinsons. Dis. 7 159–162. 10.3233/JPD-160925 27911340
Anderkova L. Barton M. Rektorova I. (2017). Striato-cortical connections in Parkinson’s and Alzheimer’s diseases: Relation to cognition. Mov. Disord. 32 917–922. 10.1002/mds.26956 28256044
Anderson R. H. Becker A. E. (1981). Stanley Kent and accessory atrioventricular connections. J. Thorac. Cardiovasc. Surg. 81 649–658.7012454
Anisuzzaman A. S. Uwada J. Masuoka T. Yoshiki H. Nishio M. Ikegaya Y. (2013). Novel contribution of cell surface and intracellular M1-muscarinic acetylcholine receptors to synaptic plasticity in hippocampus. J. Neurochem. 126 360–371. 10.1111/jnc.12306 23678982
Aosaki T. Graybiel A. M. Kimura M. (1994a). Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys. Science 265 412–415. 10.1126/science.8023166 8023166
Aosaki T. Miura M. Suzuki T. Nishimura K. Masuda M. (2010). Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int. 10 (Suppl. 1 ), S148–S157. 10.1111/j.1447-0594.2010.00588.x 20590830
Aosaki T. Tsubokawa H. Ishida A. Watanabe K. Graybiel A. M. Kimura M. (1994b). Responses of tonically active neurons in the primate’s striatum undergo systematic changes during behavioral sensorimotor conditioning. J. Neurosci. 14 3969–3984.8207500
Apicella P. (2017). The role of the intrinsic cholinergic system of the striatum: What have we learned from TAN recordings in behaving animals? Neuroscience 360 81–94. 10.1016/j.neuroscience.2017.07.060 28768155
Aquino-Miranda G. Molina-Hernandez A. Arias-Montano J. A. (2012). Regulation by histamine H3 receptors of neurotransmitter release in the basal ganglia: implications for Parkinson’s disease pathophysiology. Gac. Med. Mex. 148 467–475.23128888
Avena N. M. Rada P. V. (2012). Cholinergic modulation of food and drug satiety and withdrawal. Physiol. Behav. 106 332–336. 10.1016/j.physbeh.2012.03.020 22465312
Avramovich Y. Amit T. Youdim M. B. (2002). Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277 31466–31473. 10.1074/jbc.M201308200 12070143
Aybek S. Lazeyras F. Gronchi-Perrin A. Burkhard P. R. Villemure J. G. Vingerhoets F. J. (2009). Hippocampal atrophy predicts conversion to dementia after STN-DBS in Parkinson’s disease. Parkinsonism. Relat. Disord. 15 521–524. 10.1016/j.parkreldis.2009.01.003 19349206
Ballanger B. Klinger H. Eche J. Lerond J. Vallet A. E. Le Bars D. (2012). Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov. Disord. 27 84–89. 10.1002/mds.23895 21994070
Ballinger E. C. Ananth M. Talmage D. A. Role L. W. (2016). Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline. Neuron 91 1199–1218. 10.1016/j.neuron.2016.09.006 27657448
Bandy B. Davison A. J. (1990). Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic. Biol. Med. 8 523–539. 10.1016/0891-5849(90)90152-9 2193852
Barbeau A. (1962). The pathogenesis of Parkinson’s disease: a new hypothesis. Can. Med. Assoc. J. 87 802–807.13966498
Barreto G. E. Iarkov A. Moran V. E. (2014). Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson’s disease. Front. Aging Neurosci. 6 :340 . 10.3389/fnagi.2014.00340 25620929
Bayarsaikhan E. Bayarsaikhan D. Lee J. Son M. Oh S. Moon J. (2015). Microglial AGE-albumin is critical for neuronal death in Parkinson’s disease: a possible implication for theranostics. Int. J. Nanomed. 10 281–292. 10.2147/IJN.S95077 27601894
Beach T. G. Adler C. H. Sue L. I. Peirce J. B. Bachalakuri J. Dalsing-Hernandez J. E. (2008). Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115 445–451. 10.1007/s00401-007-0313-7 17985144
Beach T. G. White C. L. III Hladik C. L. Sabbagh M. N. Connor D. J. Shill H. A. (2009). Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 117 169–174. 10.1007/s00401-008-0450-7 18982334
Benard G. Massa F. Puente N. Lourenco J. Bellocchio L. Soria-Gomez E. (2012). Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat. Neurosci. 15 558–564. 10.1038/nn.3053 22388959
Bennett B. D. Callaway J. C. Wilson C. J. (2000). Intrinsic membrane properties underlying spontaneous tonic firing in neostriatal cholinergic interneurons. J. Neurosci. 20 8493–8503.11069957
Bergeron C. Petrunka C. Weyer L. Pollanen M. S. (1996). Altered neurofilament expression does not contribute to Lewy body formation. Am. J. Pathol. 148 267–272.8546215
Berman S. B. Miller-Patterson C. (2019). PD and DLB: Brain imaging in Parkinson’s disease and dementia with Lewy bodies. Prog. Mol. Biol. Transl. Sci. 165 167–185. 10.1016/bs.pmbts.2019.07.009 31481162
Berridge M. J. (2016). The Inositol Trisphosphate/calcium signaling pathway in health and disease. Physiol. Rev. 96 1261–1296. 10.1152/physrev.00006.2016 27512009
Bertino S. Basile G. A. Anastasi G. Bramanti A. Fonti B. Cavallaro F. (2020). Anatomical characterization of the human structural connectivity between the pedunculopontine nucleus and globus pallidus via multi-shell multi-tissue tractography. Medicina,2020 :452 . 10.3390/medicina56090452 32906651
Bharadwaj U. Kasembeli M. M. Robinson P. Tweardy D. J. (2020). Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol. Rev. 72 486–526. 10.1124/pr.119.018440 32198236
Bjorklund A. Dunnett S. B. (2007). Dopamine neuron systems in the brain: an update. Trends Neurosci. 30 194–202. 10.1016/j.tins.2007.03.006 17408759
Blanch M. Mosquera J. L. Ansoleaga B. Ferrer I. Barrachina M. (2016). Altered mitochondrial dna methylation pattern in alzheimer disease-related pathology and in parkinson disease. Am. J. Pathol. 186 385–397. 10.1016/j.ajpath.2015.10.004 26776077
Bohnen N. I. Albin R. L. (2011). The cholinergic system and Parkinson disease. Behav. Brain Res. 221 564–573. 10.1016/j.bbr.2009.12.048 20060022
Bohnen N. I. Albin R. L. Muller M. L. Chou K. (2011). Advances in therapeutic options for gait and balance in parkinson’s disease. US Neurol. 7 100–108. 10.17925/usn.2011.07.02.100 24348751
Bohnen N. I. Muller M. L. Koeppe R. A. Studenski S. A. Kilbourn M. A. Frey K. A. (2009). History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73 1670–1676. 10.1212/WNL.0b013e3181c1ded6 19917989
Boiangiu R. S. Mihasan M. Gorgan D. L. Stache B. A. Petre B. A. Hritcu L. (2020). Cotinine and 6-Hydroxy-L-Nicotine reverses memory deficits and reduces oxidative stress in abeta25-35-induced rat model of alzheimer’s disease. Antioxidants 9 :768 . 10.3390/antiox9080768 32824768
Boivin B. Vaniotis G. Allen B. G. Hebert T. E. (2008). G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J. Recept. Signal. Transduct. Res. 28 15–28. 10.1080/10799890801941889 18437627
Bolam J. P. Hanley J. J. Booth P. A. Bevan M. D. (2000). Synaptic organisation of the basal ganglia. J. Anat. 196 (Pt 4 ), 527–542. 10.1046/j.1469-7580.2000.19640527.x 10923985
Bonito-Oliva A. Masini D. Fisone G. (2014). A mouse model of non-motor symptoms in Parkinson’s disease: focus on pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci 8 :290 . 10.3389/fnbeh.2014.00290 25221486
Bonsi P. Cuomo D. Martella G. Madeo G. Schirinzi T. Puglisi F. (2011). Centrality of striatal cholinergic transmission in Basal Ganglia function. Front. Neuroanat. 5 :6 . 10.3389/fnana.2011.00006 21344017
Bordia T. Campos C. Huang L. Quik M. (2008). Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson’s disease. J. Pharmacol. Exp. Ther. 327 239–247. 10.1124/jpet.108.140897 18650244
Bordia T. Campos C. McIntosh J. M. Quik M. (2010). Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther. 333 929–938.20200117
Bordia T. McGregor M. Papke R. L. Decker M. W. McIntosh J. M. Quik M. (2015). The alpha7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp. Neurol. 263 277–284. 10.1016/j.expneurol.2014.09.015 25261754
Bordia T. Perez X. A. (2019). Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias. Eur. J. Neurosci. 49 859–868. 10.1111/ejn.14048 29923650
Bose A. Beal M. F. (2016). Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 139 (Suppl. 1 ), 216–231. 10.1111/jnc.13731 27546335
Bose A. Mouton-Liger F. Paquet C. Mazot P. Vigny M. Gray F. (2011). Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer’s disease. Brain Pathol. 21 189–200. 10.1111/j.1750-3639.2010.00437.x 21029237
Bosmans G. Shimizu Bassi G. Florens M. Gonzalez-Dominguez E. Matteoli G. Boeckxstaens G. E. (2017). Cholinergic modulation of type 2 immune responses. Front. Immunol. 8 :1873 . 10.3389/fimmu.2017.01873 29312347
Braak H. Braak E. (2000). Pathoanatomy of Parkinson’s disease. J. Neurol. 247 (Suppl. 2 ), II3–II10.10991663
Braak H. de Vos R. A. Jansen E. N. Bratzke H. Braak E. (1998). Neuropathological hallmarks of alzheimer’s and parkinson’s diseases. Prog. Brain Res. 117 267–285.9932414
Braak H. Rub U. Jansen Steur E. N. Del Tredici K. de Vos R. A. (2005). Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64 1404–1410. 10.1212/01.WNL.0000158422.41380.82 15851731
Brimblecombe K. R. Threlfell S. Dautan D. Kosillo P. Mena-Segovia J. Cragg S. J. (2018). Targeted activation of cholinergic interneurons accounts for the modulation of dopamine by striatal nicotinic receptors. eNeuro 5 :2018 . 10.1523/ENEURO.0397-17.2018 30406189
Buccafusco J. J. Terry A. V. Jr. (2003). The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci. 72 2931–2942.12706481
Buckingham S. D. Jones A. K. Brown L. A. Sattelle D. B. (2009). Nicotinic acetylcholine receptor signalling: roles in Alzheimer’s disease and amyloid neuroprotection. Pharmacol. Rev. 61 39–61.19293145
Burbulla L. F. Song P. Mazzulli J. R. Zampese E. Wong Y. C. Jeon S. (2017). Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease. Science 357 1255–1261. 10.1126/science.aam9080 28882997
Burke R. E. O’Malley K. (2013). Axon degeneration in Parkinson’s disease. Exp. Neurol. 246 72–83. 10.1016/j.expneurol.2012.01.011 22285449
Byeon H. (2020). Best early-onset Parkinson dementia predictor using ensemble learning among Parkinson’s symptoms, rapid eye movement sleep disorder, and neuropsychological profile. World J. Psychiatry 10 245–259. 10.5498/wjp.v10.i11.245 33269221
Calabresi P. Centonze D. Gubellini P. Marfia G. A. Pisani A. Sancesario G. (2000a). Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61 231–265. 10.1016/s0301-0082(99)00030-1 10727775
Calabresi P. Centonze D. Gubellini P. Pisani A. Bernardi G. (2000b). Acetylcholine-mediated modulation of striatal function. Trends Neurosci. 23 120–126. 10.1016/s0166-2236(99)01501-5 10675916
Campos H. C. da Rocha M. D. Viegas F. P. Nicastro P. C. Fossaluzza P. C. Fraga C. A. (2011). The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson’s disease. CNS Neurol. Disord. Drug Targets 10 239–250.20874702
Carey G. Gormezoglu M. de Jong J. J. A. Hofman P. A. M. Backes W. H. Dujardin K. (2021). Neuroimaging of Anxiety in Parkinson’s Disease: A Systematic Review. Mov. Disord 36 327–339. 10.1002/mds.28404 33289195
Carlsson A. Fornstedt B. (1991). Possible mechanisms underlying the special vulnerability of dopaminergic neurons. Acta Neurol. Scand. Suppl. 136 16–18. 10.1111/j.1600-0404.1991.tb05014.x 1801531
Carvey P. M. Chang Q. Lipton J. W. Ling Z. (2003). Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson’s disease. Front. Biosci. 8 :s826–s837.12957870
Cerasa A. Novellino F. Quattrone A. (2016). Connectivity changes in parkinson’s disease. Curr. Neurol. Neurosci. Rep. 16 :91 . 10.1007/s11910-016-0687-9 27568202
Chambers N. E. Meadows S. M. Taylor A. Sheena E. Lanza K. Conti M. M. (2019). Effects of muscarinic acetylcholine m1 and m4 receptor blockade on dyskinesia in the hemi-parkinsonian rat. Neuroscience 409 180–194. 10.1016/j.neuroscience.2019.04.008 31029732
Chapman M. A. (2009). Does smoking reduce the risk of Parkinson’s disease through stimulation of the ubiquitin-proteasome system? Med. Hypotheses 73 887–891. 10.1016/j.mehy.2009.03.053 19540050
Charara A. Parent A. (1994). Brainstem dopaminergic, cholinergic and serotoninergic afferents to the pallidum in the squirrel monkey. Brain Res. 640 155–170. 10.1016/0006-8993(94)91870-8 7911724
Chen H. Huang X. Guo X. Mailman R. B. Park Y. Kamel F. (2010). Smoking duration, intensity, and risk of Parkinson disease. Neurology 74 878–884. 10.1212/WNL.0b013e3181d55f38 20220126
Chen L. Yamada K. Nabeshima T. Sokabe M. (2006). alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50 254–268. 10.1016/j.neuropharm.2005.09.018 16324726
Cheng Y. Wang Y. J. (2020). Tobacco smoking and the reduced risk of Parkinson disease: A puzzle of 60 years. Neurology 94 860–861. 10.1212/WNL.0000000000009431 32371449
Cholerton B. Johnson C. O. Fish B. Quinn J. F. Chung K. A. Peterson-Hiller A. L. (2018). Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat. Disord. 50 29–36. 10.1016/j.parkreldis.2018.02.007 29478836
Chondrogiorgi M. Astrakas L. G. Zikou A. K. Weis L. Xydis V. G. Antonini A. (2019). Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson’s disease patients. Brain Imag. Behav. 13 232–240. 10.1007/s11682-018-9863-7 29629498
Chung C. Y. Seo H. Sonntag K. C. Brooks A. Lin L. Isacson O. (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14 1709–1725. 10.1093/hmg/ddi178 15888489
Chung S. J. Yoo H. S. Lee Y. H. Lee H. S. Ye B. S. Sohn Y. H. (2019). Frontal atrophy as a marker for dementia conversion in Parkinson’s disease with mild cognitive impairment. Hum. Brain Mapp. 40 3784–3794. 10.1002/hbm.24631 31090134
Chung S. J. Yoo H. S. Shin N. Y. Park Y. W. Lee H. S. Hong J. M. (2021). Perivascular spaces in the basal ganglia and long-term motor prognosis in newly diagnosed parkinson disease. Neurology 96 e2121–e2131. 10.1212/WNL.0000000000011797 33653906
Clarke R. Adermark L. (2015). Dopaminergic regulation of striatal interneurons in reward and addiction: focus on alcohol. Neural. Plast. 2015 :814567 . 10.1155/2015/814567 26246915
Compta Y. Revesz T. (2021). Neuropathological and biomarker findings in parkinson’s disease and alzheimer’s disease: from protein aggregates to synaptic dysfunction. J. Parkinsons. Dis. 11 107–121. 10.3233/JPD-202323 33325398
Consolo S. Girotti P. Zambelli M. Russi G. Benzi M. Bertorelli R. (1993). D1 and D2 dopamine receptors and the regulation of striatal acetylcholine release in vivo. Prog. Brain Res. 98 201–207. 10.1016/s0079-6123(08)62400-0 7902591
Conti M. M. Chambers N. Bishop C. (2018). A new outlook on cholinergic interneurons in Parkinson’s disease and L-DOPA-induced dyskinesia. Neurosci. Biobehav. Rev. 92 67–82. 10.1016/j.neubiorev.2018.05.021 29782883
Cooper J. A. Sagar H. J. Doherty S. M. Jordan N. Tidswell P. Sullivan E. V. (1992). Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 115 (Pt 6 ), 1701–1725. 10.1093/brain/115.6.1701 1486457
Course M. M. Wang X. (2016). Transporting mitochondria in neurons. F1000Res 5 :7864 . 10.12688/f1000research.7864.1 27508065
Court J. A. Piggott M. A. Lloyd S. Cookson N. Ballard C. G. McKeith I. G. (2000). Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 98 79–87.10858614
Crans R. A. J. Ciruela F. (2021). Dopaminergic-cholinergic imbalance in movement disorders: a role for the novel striatal dopamine D2- muscarinic acetylcholine M1 receptor heteromer. Neural. Regen. Res. 16 1406–1408. 10.4103/1673-5374.300988 33318429
Crispo J. A. Willis A. W. Thibault D. P. Fortin Y. Hays H. D. McNair D. S. (2016). Associations between anticholinergic burden and adverse health outcomes in parkinson disease. PLoS One 11 :e0150621 . 10.1371/journal.pone.0150621 26939130
Dajas-Bailador F. Wonnacott S. (2004). Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol. Sci. 25 317–324. 10.1016/j.tips.2004.04.006 15165747
Damsma G. Robertson G. S. Tham C. S. Fibiger H. C. (1991). Dopaminergic regulation of striatal acetylcholine release: importance of D1 and N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 259 1064–1072.1837058
Dani J. A. (2015). Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int. Rev. Neurobiol. 124 3–19. 10.1016/bs.irn.2015.07.001 26472524
Dautan D. Huerta-Ocampo I. Gut N. K. Valencia M. Kondabolu K. Kim Y. (2020). Cholinergic midbrain afferents modulate striatal circuits and shape encoding of action strategies. Nat. Commun. 11 :1739 . 10.1038/s41467-020-15514-3 32269213
Dautan D. Huerta-Ocampo I. Witten I. B. Deisseroth K. Bolam J. P. Gerdjikov T. (2014). A major external source of cholinergic innervation of the striatum and nucleus accumbens originates in the brainstem. J. Neurosci. 34 4509–4518. 10.1523/JNEUROSCI.5071-13.2014 24671996
de Aguiar R. B. Parfitt G. M. Jaboinski J. Barros D. M. (2013). Neuroactive effects of cotinine on the hippocampus: behavioral and biochemical parameters. Neuropharmacology 71 292–298.23602986
de Jonge W. J. Ulloa L. (2007). The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol. 151 915–929.17502850
Deffains M. Bergman H. (2015). Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease. Mov. Disord. 30 1014–1025. 10.1002/mds.26300 26095280
Delic V. Beck K. D. Pang K. C. H. Citron B. A. (2020). Biological links between traumatic brain injury and Parkinson’s disease. Acta Neuropathol. Commun. 8 :45 . 10.1186/s40478-020-00924-7 32264976
DeLong M. (2000). Parkinson’s disease. Neurobiol. Dis. 7 559–560. 10.1006/nbdi.2000.0355 11042077
Deng H. Wang P. Jankovic J. (2018). The genetics of Parkinson disease. Ageing Res. Rev. 42 72–85. 10.1016/j.arr.2017.12.007 29288112
Deng J. Habib A. Obregon D. F. Barger S. W. Giunta B. Wang Y. J. (2015). Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3beta signaling pathway. J Neurochem 135 630–637. 10.1111/jnc.13351 26342176
Devi L. Raghavendran V. Prabhu B. M. Avadhani N. G. Anandatheerthavarada H. K. (2008). Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283 9089–9100. 10.1074/jbc.M710012200 18245082
Dexter D. T. Jenner P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol. Med. 62 132–144. 10.1016/j.freeradbiomed.2013.01.018 23380027
Di Chiara G. Morelli M. Consolo S. (1994). Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 17 228–233. 10.1016/0166-2236(94)90005-1 7521083
Dineley K. T. Pandya A. A. Yakel J. L. (2015). Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol. Sci. 36 96–108. 10.1016/j.tips.2014.12.002 25639674
Do J. Kim J. I. Bakes J. Lee K. Kaang B. K. (2012). Functional roles of neurotransmitters and neuromodulators in the dorsal striatum. Learn Mem. 20 21–28. 10.1101/lm.025015.111 23247251
Dos Santos T. F. O. de R. S. E. Bispo J. M. M. de Souza M. F. de Gois A. M. Lins L. (2021). Balance alterations and reduction of pedunculopontine cholinergic neurons in early stages of parkinsonism in middle-aged rats. Exp. Gerontol. 145 :111198 . 10.1016/j.exger.2020.111198 33310153
Drachman D. A. Leavitt J. (1974). Human memory and the cholinergic system. A relationship to aging? Arch. Neurol. 30 113–121. 10.1001/archneur.1974.00490320001001 4359364
Duce J. A. Wong B. X. Durham H. Devedjian J. C. Smith D. P. Devos D. (2017). Post translational changes to alpha-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease. Mol. Neurodegener. 12 :45 . 10.1186/s13024-017-0186-8 28592304
Durieux P. F. Schiffmann S. N. de Kerchove d’Exaerde A. (2011). Targeting neuronal populations of the striatum. Front. Neuroanat. 5 :40 . 10.3389/fnana.2011.00040 21811438
Echeverria V. Grizzell J. A. Barreto G. E. (2016a). Neuroinflammation: a therapeutic target of cotinine for the treatment of psychiatric disorders? Curr. Pharm. Des. 22 1324–1333.26972290
Echeverria V. Yarkov A. Aliev G. (2016b). Positive modulators of the alpha7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer’s disease. Prog. Neurobiol. 144 142–157. 10.1016/j.pneurobio.2016.01.002 26797042
Echeverria V. Zeitlin R. (2012). Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci. Ther. 18 517–523. 10.1111/j.1755-5949.2012.00317.x 22530628
Echeverria V. Zeitlin R. Burgess S. Patel S. Barman A. Thakur G. (2011). Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer’s disease mice. J. Alzheimers Dis. 24 817–835. 10.3233/JAD-2011-102136 21321389
Eisinger R. S. Ramirez-Zamora A. Carbunaru S. Ptak B. Peng-Chen Z. Okun M. S. (2019). Medications, deep brain stimulation, and other factors influencing impulse control disorders in parkinson’s disease. Front. Neurol. 10 :86 . 10.3389/fneur.2019.00086 30863353
Emre M. Aarsland D. Brown R. Burn D. J. Duyckaerts C. Mizuno Y. (2007). Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord. 22 1689–1707. 10.1002/mds.21507 17542011
Eneroth P. Fuxe K. Gustafsson J. A. Hokfelt T. Lofstrom A. Skett P. (1977). The effect of nicotine on central catecholamine neurons and gonadotropin secretion. III. Studies on prepubertal female rats treated with pregnant mare serum gonadotropin. Med. Biol. 55 167–176.895215
English D. F. Ibanez-Sandoval O. Stark E. Tecuapetla F. Buzsaki G. Deisseroth K. (2011). GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons. Nat. Neurosci. 15 123–130. 10.1038/nn.2984 22158514
Fahn S. (1989). The history of parkinsonism. Mov. Disord. 4 (Suppl. 1 ), S2–S10. 10.1002/mds.870040502 2657407
Falkenburger B. H. Jensen J. B. Hille B. (2010). Kinetics of PIP2 metabolism and KCNQ2/3 channel regulation studied with a voltage-sensitive phosphatase in living cells. J. Gen. Physiol. 135 99–114. 10.1085/jgp.200910345 20100891
Farias G. G. Godoy J. A. Hernandez F. Avila J. Fisher A. Inestrosa N. C. (2004). M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol. Dis. 17 337–348. 10.1016/j.nbd.2004.07.016 15474371
Ferre S. Ciruela F. (2019). Functional and neuroprotective role of striatal adenosine A2A Receptor Heterotetramers. J. Caffeine Adenosine Res. 9 89–97. 10.1089/caff.2019.0008 31559390
Ferre S. Lluis C. Justinova Z. Quiroz C. Orru M. Navarro G. (2010). Adenosine-cannabinoid receptor interactions. Implications for striatal function. Br. J. Pharmacol. 160 443–453. 10.1111/j.1476-5381.2010.00723.x 20590556
Ferrer I. Lopez-Gonzalez I. Carmona M. Dalfo E. Pujol A. Martinez A. (2012). Neurochemistry and the non-motor aspects of PD. Neurobiol. Dis. 46 508–526. 10.1016/j.nbd.2011.10.019 22737710
Ferrer I. Martinez A. Blanco R. Dalfo E. Carmona M. (2011). Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J. Neural. Transm. 118 821–839. 10.1007/s00702-010-0482-8 20862500
Fitts W. Weintraub D. Massimo L. Chahine L. Chen-Plotkin A. Duda J. E. (2015). Caregiver report of apathy predicts dementia in Parkinson’s disease. Parkinsonism. Relat. Disord. 21 992–995. 10.1016/j.parkreldis.2015.06.009 26117435
Foltynie T. Brayne C. Barker R. A. (2002a). The heterogeneity of idiopathic Parkinson’s disease. J. Neurol. 249 138–145. 10.1007/pl00007856 11985378
Foltynie T. Sawcer S. Brayne C. Barker R. A. (2002b). The genetic basis of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 73 363–370. 10.1136/jnnp.73.4.363 12235301
Foster P. S. Drago V. Mendez K. Witt J. C. Crucian G. P. Heilman K. M. (2013). Mood disturbances and cognitive functioning in Parkinson’s disease: the effects of disease duration and side of onset of motor symptoms. J. Clin. Exp. Neuropsychol. 35 71–82. 10.1080/13803395.2012.753037 23320400
Fox A. M. Moonschi F. H. Richards C. I. (2015). The nicotine metabolite, cotinine, alters the assembly and trafficking of a subset of nicotinic acetylcholine receptors. J. Biol. Chem. 290 24403–24412. 10.1074/jbc.M115.661827 26269589
Franco-Iborra S. Vila M. Perier C. (2016). The parkinson disease mitochondrial hypothesis: where are we at? Neuroscientist 22 266–277. 10.1177/1073858415574600 25761946
Fratiglioni L. Wang H. X. (2000). Smoking and Parkinson’s and Alzheimer’s disease: review of the epidemiological studies. Behav. Brain Res. 113 117–120. 10.1016/s0166-4328(00)00206-0 10942038
French I. T. Muthusamy K. A. (2018). A review of the pedunculopontine nucleus in parkinson’s disease. Front. Aging. Neurosci. 10 :99 . 10.3389/fnagi.2018.00099 29755338
Friedman J. H. (2018). Dementia with lewy bodies and parkinson disease dementia: it is the same disease! Parkinsonism Relat. Disord. 46 (Suppl. 1 ), S6–S9. 10.1016/j.parkreldis.2017.07.013 28756177
Fujii S. Ji Z. Morita N. Sumikawa K. (1999). Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res. 846 137–143. 10.1016/s0006-8993(99)01982-4 10536221
Fujii T. Mashimo M. Moriwaki Y. Misawa H. Ono S. Horiguchi K. (2017). Physiological functions of the cholinergic system in immune cells. J. Pharmacol. Sci. 134 1–21. 10.1016/j.jphs.2017.05.002 28552584
Fuxe K. Andersson K. Harfstrand A. Agnati L. F. (1986). Increases in dopamine utilization in certain limbic dopamine terminal populations after a short period of intermittent exposure of male rats to cigarette smoke. J. Neural. Transm. 67 15–29.2878061
Fuxe K. Everitt B. J. Hokfelt T. (1979). On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol. Biochem. Behav. 10 671–677.493284
Galantucci S. Agosta F. Stefanova E. Basaia S. van den Heuvel M. P. Stojkovic T. (2017). Structural Brain Connectome and Cognitive Impairment in Parkinson Disease. Radiology 283 515–525. 10.1148/radiol.2016160274 27924721
Gale J. T. Amirnovin R. Williams Z. M. Flaherty A. W. Eskandar E. N. (2008). From symphony to cacophony: pathophysiology of the human basal ganglia in Parkinson disease. Neurosci. Biobehav. Rev. 32 378–387. 10.1016/j.neubiorev.2006.11.005 17466375
Gallo E. F. (2019). Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior. Neurochem. Int. 125 35–46. 10.1016/j.neuint.2019.01.022 30716356
Gallo V. Vineis P. Cancellieri M. Chiodini P. Barker R. A. Brayne C. (2019). Exploring causality of the association between smoking and Parkinson’s disease. Int. J. Epidemiol. 48 912–925. 10.1093/ije/dyy230 30462234
Gao J. Adam B. L. Terry A. V. Jr. (2014). Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer’s disease. Bioorg. Med. Chem. Lett. 24 1472–1478. 10.1016/j.bmcl.2014.02.008 24581918
Garcia-Rill E. (1986). The basal ganglia and the locomotor regions. Brain Res. 396 47–63.2871904
Gelb D. J. Oliver E. Gilman S. (1999). Diagnostic criteria for Parkinson disease. Arch. Neurol. 56 33–39.9923759
George S. Rey N. L. Reichenbach N. Steiner J. A. Brundin P. (2013). alpha-Synuclein: the long distance runner. Brain Pathol 23 350–357. 10.1111/bpa.12046 23587141
Gerfen C. R. Surmeier D. J. (2011). Modulation of striatal projection systems by dopamine. Annu Rev. Neurosci. 34 441–466. 10.1146/annurev-neuro-061010-113641 21469956
Gergalova G. Lykhmus O. Komisarenko S. Skok M. (2014). alpha7 nicotinic acetylcholine receptors control cytochrome c release from isolated mitochondria through kinase-mediated pathways. Int. J. Biochem. Cell Biol. 49 26–31. 10.1016/j.biocel.2014.01.001 24412630
Getachew B. Csoka A. B. Aschner M. Tizabi Y. (2019). Nicotine protects against manganese and iron-induced toxicity in SH-SY5Y cells: Implication for Parkinson’s disease. Neurochem. Int. 124 19–24. 10.1016/j.neuint.2018.12.003 30557592
Gilmozzi V. Gentile G. Castelo Rueda M. P. Hicks A. A. Pramstaller P. P. Zanon A. (2020). Interaction of alpha-synuclein with lipids: mitochondrial cardiolipin as a critical player in the pathogenesis of parkinson’s disease. Front. Neurosci. 14 :578993 . 10.3389/fnins.2020.578993 33122994
Goldberg J. A. Ding J. B. Surmeier D. J. (2012). Muscarinic modulation of striatal function and circuitry. Handb. Exp. Pharmacol. 208 223–241. 10.1007/978-3-642-23274-9_10
Goldberg J. A. Reynolds J. N. (2011). Spontaneous firing and evoked pauses in the tonically active cholinergic interneurons of the striatum. Neuroscience 198 27–43. 10.1016/j.neuroscience.2011.08.067 21925242
Gonzales K. K. Smith Y. (2015). Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. Ann. N. Y. Acad. Sci. 1349 1–45. 10.1111/nyas.12762 25876458
Gotti C. Clementi F. Fornari A. Gaimarri A. Guiducci S. Manfredi I. (2009). Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 78 703–711. 10.1016/j.bcp.2009.05.024 19481063
Graef S. Schonknecht P. Sabri O. Hegerl U. (2011). Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology 215 205–229. 10.1007/s00213-010-2153-8 21212938
Green J. McDonald W. M. Vitek J. L. Evatt M. Freeman A. Haber M. (2002). Cognitive impairments in advanced PD without dementia. Neurology 59 1320–1324. 10.1212/01.wnl.0000031426.21683.e2 12427877
Greenbaum L. Rigbi A. Lipshtat N. Cilia R. Tesei S. Asselta R. (2013). Association of nicotine dependence susceptibility gene. CHRNA5, with Parkinson’s disease age at onset: gene and smoking status interaction. Parkinsonism Relat. Disord. 19 72–76. 10.1016/j.parkreldis.2012.07.007 22884254
Grizzell J. A. Echeverria V. (2015). New insights into the mechanisms of action of cotinine and its distinctive effects from nicotine. Neurochem. Res. 40 2032–2046. 10.1007/s11064-014-1359-2 24970109
Grizzell J. A. Iarkov A. Holmes R. Mori T. Echeverria V. (2014). Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice. Behav. Brain Res. 268 55–65. 10.1016/j.bbr.2014.03.047 24713149
Grizzell J. A. Patel S. Barreto G. E. Echeverria V. (2017). Cotinine improves visual recognition memory and decreases cortical Tau phosphorylation in the Tg6799 mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 78 75–81. 10.1016/j.pnpbp.2017.05.010 28536070
Grover S. Somaiya M. Kumar S. Avasthi A. (2015). Psychiatric aspects of Parkinson’s disease. J. Neurosci. Rural. Pract. 6 65–76. 10.4103/0976-3147.143197 25552854
Grunewald A. Kumar K. R. Sue C. M. (2019). New insights into the complex role of mitochondria in Parkinson’s disease. Prog. Neurobiol. 177 73–93. 10.1016/j.pneurobio.2018.09.003 30219247
Guo Y. Xu W. Liu F. T. Li J. Q. Cao X. P. Tan L. (2019). Modifiable risk factors for cognitive impairment in Parkinson’s disease: a systematic review and meta-analysis of prospective cohort studies. Mov. Disord. 34 876–883. 10.1002/mds.27665 30869825
Guttuso T. Jr. (2019). High lithium levels in tobacco may account for reduced incidences of both Parkinson’s disease and melanoma in smokers through enhanced beta-catenin-mediated activity. Med. Hypotheses 131 :109302 . 10.1016/j.mehy.2019.109302 31443765
Guttuso T. Jr. Andrzejewski K. L. Lichter D. G. Andersen J. K. (2019a). Targeting kinases in Parkinson’s disease: a mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J. Neurol. Sci. 402 121–130. 10.1016/j.jns.2019.05.016 31129265
Guttuso T. Jr. Russak E. De Blanco M. T. Ramanathan M. (2019b). Could high lithium levels in tobacco contribute to reduced risk of Parkinson’s disease in smokers? J. Neurol. Sci. 397 179–180. 10.1016/j.jns.2019.01.009 30641248
Habib A. Sawmiller D. Tan J. (2017). Restoring soluble amyloid precursor protein alpha functions as a potential treatment for alzheimer’s disease. J. Neurosci. Res. 95 973–991. 10.1002/jnr.23823 27531392
Halder N. Lal G. (2021). Cholinergic System and Its Therapeutic Importance in Inflammation and Autoimmunity. Front. Immunol. 12 :660342 . 10.3389/fimmu.2021.660342 33936095
Hampel H. Mesulam M. M. Cuello A. C. Farlow M. R. Giacobini E. Grossberg G. T. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141 1917–1933. 10.1093/brain/awy132 29850777
Hasan S. Mielke M. M. Turcano P. Ahlskog J. E. Bower J. H. Savica R. (2020). Traumatic brain injury preceding clinically diagnosed alpha-synucleinopathies: A case-control study. Neurology 94 e764–e773. 10.1212/WNL.0000000000008995 31992680
Hatsukami D. K. Grillo M. Pentel P. R. Oncken C. Bliss R. (1997). Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol. Biochem. Behav. 57 643–650.9258989
Havekes R. Abel T. Van der Zee E. A. (2011). The cholinergic system and neostriatal memory functions. Behav. Brain Res 221 412–423. 10.1016/j.bbr.2010.11.047 21129408
Hegarty S. V. Sullivan A. M. O’Keeffe G. W. (2013). Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Dev. Biol. 379 123–138. 10.1016/j.ydbio.2013.04.014 23603197
Hemmerle A. M. Herman J. P. Seroogy K. B. (2012). Stress, depression and Parkinson’s disease. Exp. Neurol. 233 79–86. 10.1016/j.expneurol.2011.09.035 22001159
Herzallah M. M. Moustafa A. A. Misk A. J. Al-Dweib L. H. Abdelrazeq S. A. Myers C. E. (2010). Depression impairs learning whereas anticholinergics impair transfer generalization in Parkinson patients tested on dopaminergic medications. Cogn. Behav. Neurol. 23 98–105. 10.1097/WNN.0b013e3181df3048 20535058
Hill W. D. (1996). Altered neurofilament expression does not contribute to Lewy body formation. Am. J. Pathol. 149 728–729.8702011
Ho M. W. Chien S. H. Lu M. K. Chen J. C. Aoh Y. Chen C. M. (2020). Impairments in face discrimination and emotion recognition are related to aging and cognitive dysfunctions in Parkinson’s disease with dementia. Sci. Rep. 10 :4367 . 10.1038/s41598-020-61310-w 32152359
Hong D. P. Fink A. L. Uversky V. N. (2009). Smoking and Parkinson’s disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta 1794 282–290. 10.1016/j.bbapap.2008.09.026 19013262
Hoogland J. Boel J. A. de Bie R. M. A. Geskus R. B. Schmand B. A. Dalrymple-Alford J. C. (2017). Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Mov. Disord 32 1056–1065. 10.1002/mds.27002 28605056
Horowitz M. P. Milanese C. Di Maio R. Hu X. Montero L. M. Sanders L. H. (2011). Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. Antioxid. Redox Signal. 15 855–871. 10.1089/ars.2010.3629 21395478
Howe W. M. Young D. A. Bekheet G. Kozak R. (2016). Nicotinic receptor subtypes differentially modulate glutamate release in the dorsal medial striatum. Neurochem. Int. 100 30–34. 10.1016/j.neuint.2016.08.009 27568861
Huang L. Z. Campos C. Ly J. Ivy Carroll F. Quik M. (2011a). Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60 861–868. 10.1016/j.neuropharm.2010.12.032 21232546
Huang L. Z. Grady S. R. Quik M. (2011b). Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2∗ nicotinic receptors. J. Pharmacol. Exp. Ther. 338 932–941. 10.1124/jpet.111.182949 21665941
Huang L. Z. Parameswaran N. Bordia T. Michael, McIntosh J. Quik M. (2009). Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J. Neurochem. 109 826–837. 10.1111/j.1471-4159.2009.06011.x 19250334
Huang Y. Thathiah A. (2015). Regulation of neuronal communication by G protein-coupled receptors. FEBS Lett. 589 1607–1619. 10.1016/j.febslet.2015.05.007 25980603
Huang Y. Y. Kandel E. R. Levine A. (2008). Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of LTP in the amygdala. Learn Mem. 15 603–610. 10.1101/lm.975308 18685152
Huerta-Ocampo I. Dautan D. Gut N. K. Khan B. Mena-Segovia J. (2021). Whole-brain mapping of monosynaptic inputs to midbrain cholinergic neurons. Sci. Rep. 11 :9055 . 10.1038/s41598-021-88374-6 33907215
Hussain M. W. Camicioli R. (2018). Nonmotor symptoms of parkinson’s disease as predictors of dementia. Can. J. Neurol. Sci. 45 97–99. 10.1017/cjn.2017.239 29113606
Hussein A. Guevara C. A. Del Valle P. Gupta S. Benson D. L. Huntley G. W. (2021). Non-motor symptoms of parkinson’s disease: the neurobiology of early psychiatric and cognitive dysfunction. Neuroscientist 2021 :011979 . 10.1177/10738584211011979 33966533
Iarkov A. Barreto G. E. Grizzell J. A. Echeverria V. (2020). Strategies for the treatment of parkinson’s disease: beyond dopamine. Front. Aging Neurosci. 12 :4 . 10.3389/fnagi.2020.00004 32076403
Irwin M. H. Moos W. H. Faller D. V. Steliou K. Pinkert C. A. (2016). Epigenetic treatment of neurodegenerative disorders: alzheimer and parkinson diseases. Drug Dev. Res. 77 109–123. 10.1002/ddr.21294 26899010
Janickova H. Rudajev V. Zimcik P. Jakubik J. Tanila H. El-Fakahany E. E. (2013). Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42). Neuropharmacology 67 272–283. 10.1016/j.neuropharm.2012.11.014 23206502
Jiang J. Shi S. Zhou Q. Ma X. Nie X. Yang L. (2014a). Downregulation of the Wnt/beta-catenin signaling pathway is involved in manganese-induced neurotoxicity in rat striatum and PC12 cells. J. Neurosci. Res. 92 783–794. 10.1002/jnr.23352 24464479
Jiang L. Kundu S. Lederman J. D. Lopez-Hernandez G. Y. Ballinger E. C. Wang S. (2016). Cholinergic signaling controls conditioned fear behaviors and enhances plasticity of cortical-amygdala circuits. Neuron 90 1057–1070. 10.1016/j.neuron.2016.04.028 27161525
Jiang P. Dickson D. W. (2018). Parkinson’s disease: experimental models and reality. Acta Neuropathol. 135 13–32. 10.1007/s00401-017-1788-5 29151169
Jiang S. Li Y. Zhang C. Zhao Y. Bu G. Xu H. (2014b). M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neurosci. Bull. 30 295–307. 10.1007/s12264-013-1406-z 24590577
Johnston T. H. Geva M. Steiner L. Orbach A. Papapetropoulos S. Savola J. M. (2019). Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Mov. Disord. 34 708–716. 10.1002/mds.27565 30575996
Jong Y. I. Harmon S. K. O’Malley K. L. (2018). Intracellular GPCRs play key roles in synaptic plasticity. ACS Chem. Neurosci. 9 2162–2172. 10.1021/acschemneuro.7b00516 29409317
Jong Y. J. Kumar V. O’Malley K. L. (2009). Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J. Biol. Chem. 284 35827–35838. 10.1074/jbc.M109.046276 19840937
Jurado-Coronel J. C. Avila-Rodriguez M. Capani F. Gonzalez J. Moran V. E. Barreto G. E. (2016). Targeting the nicotinic acetylcholine receptors (nachrs) in astrocytes as a potential therapeutic target in parkinson’s disease. Curr. Pharm. Des. 22 1305–1311. 10.2174/138161282210160304112133 26972289
Jurado-Coronel J. C. Loaiza A. E. Diaz J. E. Cabezas R. Ashraf G. M. Sahebkar A. (2019). (E)-Nicotinaldehyde O-cinnamyloxime, a nicotine analog, attenuates neuronal cells death against rotenone-induced neurotoxicity. Mol. Neurobiol. 56 1221–1232. 10.1007/s12035-018-1163-0 29881944
Kaiser S. Wonnacott S. (2000). alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 58 312–318. 10.1124/mol.58.2.312 10908298
Kalaitzakis M. E. Graeber M. B. Gentleman S. M. Pearce R. K. (2008). Striatal beta-amyloid deposition in Parkinson disease with dementia. J. Neuropathol. Exp. Neurol. 67 155–161.18219254
Kawamata J. Shimohama S. (2011). Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer’s and Parkinson’s diseases. J. Alzheimers. Dis. 24 (Suppl. 2 ), 95–109. 10.3233/JAD-2011-110173 21403387
Kawamata J. Suzuki S. Shimohama S. (2011). Enhancement of nicotinic receptors alleviates cytotoxicity in neurological disease models. Ther. Adv. Chronic. Dis. 2 197–208. 10.1177/2040622310397691 23251750
Kawamata J. Suzuki S. Shimohama S. (2012). alpha7 nicotinic acetylcholine receptor mediated neuroprotection in Parkinson’s disease. Curr. Drug. Targets 13 623–630. 10.2174/138945012800399026 22300030
Keane P. C. Kurzawa M. Blain P. G. Morris C. M. (2011). Mitochondrial dysfunction in Parkinson’s disease. Parkinsons. Dis. 2011 :716871 . 10.4061/2011/716871 21461368
Kellis D. M. Kaigler K. F. Witherspoon E. Fadel J. R. Wilson M. A. (2020). Cholinergic neurotransmission in the basolateral amygdala during cued fear extinction. Neurobiol. Stress 13 :100279 . 10.1016/j.ynstr.2020.100279 33344731
Kihara T. Shimohama S. Sawada H. Honda K. Nakamizo T. Shibasaki H. (2001). alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J. Biol. Chem. 276 13541–13546. 10.1074/jbc.M008035200 11278378
Kim M. J. Park M. Kim D. W. Shin M. J. Son O. Jo H. S. (2015). Transduced PEP-1-PON1 proteins regulate microglial activation and dopaminergic neuronal death in a Parkinson’s disease model. Biomaterials 64 45–56. 10.1016/j.biomaterials.2015.06.015 26117230
Kim R. Yoo D. Jung Y. J. Han K. Lee J. Y. (2020). Smoking cessation, weight change, and risk of parkinson’s disease: analysis of national cohort data. J. Clin. Neurol. 16 455–460. 10.3988/jcn.2020.16.3.455 32657067
Kim T. Capps R. A. Hamade K. C. Barnett W. H. Todorov D. I. Latash E. M. (2019). The functional role of striatal cholinergic interneurons in reinforcement learning from computational perspective. Front. Neural. Circuits 13 :10 . 10.3389/fncir.2019.00010 30846930
Kline E. M. Houser M. C. Herrick M. K. Seibler P. Klein C. West A. (2020). Genetic and environmental factors in parkinson’s disease converge on immune function and inflammation. Mov. Disord. 2020 :28411 . 10.1002/mds.28411 33314312
Koh Y. Y. Jang S. J. Lim D. Y. (2003). Cotinine inhibits catecholamine release evoked by cholinergic stimulation from the rat adrenal medulla. Arch. Pharm. Res. 26 747–755.14560925
Kondabolu K. Roberts E. A. Bucklin M. McCarthy M. M. Kopell N. Han X. (2016). Striatal cholinergic interneurons generate beta and gamma oscillations in the corticostriatal circuit and produce motor deficits. Proc. Natl. Acad. Sci. U S A 113 E3159–E3168. 10.1073/pnas.1605658113 27185924
Koziorowski D. Figura M. Milanowski L. M. Szlufik S. Alster P. Madetko N. (2021). Mechanisms of neurodegeneration in various forms of parkinsonism-similarities and differences. Cells 10 :656 . 10.3390/cells10030656 33809527
Kreitzer A. C. Malenka R. C. (2008). Striatal plasticity and basal ganglia circuit function. Neuron 60 543–554. 10.1016/j.neuron.2008.11.005 19038213
Kroker K. S. Rast G. Rosenbrock H. (2011). Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP. Eur. J. Pharmacol. 671 26–32. 10.1016/j.ejphar.2011.09.167 21968142
Kruse A. C. Kobilka B. K. Gautam D. Sexton P. M. Christopoulos A. Wess J. (2014). Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat. Rev. Drug Discov. 13 549–560. 10.1038/nrd4295 24903776
Kucinski A. Sarter M. (2015). Modeling Parkinson’s disease falls associated with brainstem cholinergic systems decline. Behav. Neurosci. 129 96–104. 10.1037/bne0000048 25798629
Kwon K. Y. Lee E. J. Lee M. Ju H. Im K. (2021). Impact of motor subtype on non-motor symptoms and fall-related features in patients with early Parkinson’s disease. Geriatr. Gerontol. Int. 21 416–420. 10.1111/ggi.14156 33780137
Kyaw W. T. Nagai M. Kaneta M. Kubo M. Nishikawa N. Tsujii T. (2013). Effect of nicotine on the pharmacokinetics of levodopa. Clin. Neuropharmacol. 36 46–51. 10.1097/WNF.0b013e31827fd9cd 23503546
Langmead C. J. Austin N. E. Branch C. L. Brown J. T. Buchanan K. A. Davies C. H. (2008a). Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br. J. Pharmacol. 154 1104–1115. 10.1038/bjp.2008.152 18454168
Langmead C. J. Watson J. Reavill C. (2008b). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117 232–243. 10.1016/j.pharmthera.2007.09.009 18082893
Lanskey J. H. McColgan P. Schrag A. E. Acosta-Cabronero J. Rees G. Morris H. R. (2018). Can neuroimaging predict dementia in Parkinson’s disease? Brain 141 2545–2560. 10.1093/brain/awy211 30137209
Lee J. Kim C. H. Simon D. K. Aminova L. R. Andreyev A. Y. Kushnareva Y. E. (2005). Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280 40398–40401.16207717
Lee J. A. Kim J. H. Woo S. Y. Son H. J. Han S. H. Jang B. K. (2015). A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia and in Parkinson’s disease animal model. Br. J. Pharmacol. 172 1087–1100. 10.1111/bph.12973 25297649
Leinninger G. M. Backus C. Uhler M. D. Lentz S. I. Feldman E. L. (2004). Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons. FASEB J. 18 1544–1546. 10.1096/fj.04-1581fje 15319368
Lenka N. Vijayasarathy C. Mullick J. Avadhani N. G. (1998). Structural organization and transcription regulation of nuclear genes encoding the mammalian cytochrome c oxidase complex. Prog. Nucleic Acid Res. Mol. Biol. 61 309–344.9752724
L’Episcopo F. Tirolo C. Testa N. Caniglia S. Morale M. C. Serapide M. F. (2014). Wnt/beta-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson’s disease. Stem Cells 32 2147–2163. 10.1002/stem.1708 24648001
Lester D. B. Rogers T. D. Blaha C. D. (2010). Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16 137–162. 10.1111/j.1755-5949.2010.00142.x 20370804
Lester H. A. Xiao C. Srinivasan R. Son C. D. Miwa J. Pantoja R. (2009). Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J 11 167–177. 10.1208/s12248-009-9090-7 19280351
Leverenz J. B. Quinn J. F. Zabetian C. Zhang J. Montine K. S. Montine T. J. (2009). Cognitive impairment and dementia in patients with Parkinson disease. Curr. Top. Med. Chem. 9 903–912.19754405
Lieberman A. Lockhart T. E. Olson M. C. Smith Hussain V. A. Frames C. W. Sadreddin A. (2019). Nicotine bitartrate reduces falls and freezing of gait in parkinson disease: a reanalysis. Front. Neurol. 10 :424 . 10.3389/fneur.2019.00424 31133957
Lim S. A. Kang U. J. McGehee D. S. (2014). Striatal cholinergic interneuron regulation and circuit effects. Front. Synaptic. Neurosci. 6 :22 . 10.3389/fnsyn.2014.00022 25374536
Lindqvist D. Kaufman E. Brundin L. Hall S. Surova Y. Hansson O. (2012). Non-motor symptoms in patients with Parkinson’s disease - correlations with inflammatory cytokines in serum. PLoS One 7 :e47387 .
Linert W. Bridge M. H. Huber M. Bjugstad K. B. Grossman S. Arendash G. W. (1999). In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson’s and Alzheimer’s diseases. Biochim. Biophys. Acta 1454 143–152.10381559
Liu C. (2020). Targeting the cholinergic system in Parkinson’s disease. Acta Pharmacol. Sin. 41 453–463. 10.1038/s41401-020-0380-z 32132659
Liu Q. Q. Ding S. K. Zhang H. Shang Y. Z. (2021). The molecular mechanism of scutellaria baicalensis georgi stems and leaves flavonoids in promoting neurogenesis and improving memory impairment by the PI3K-AKT-CREB Signaling Pathway in Rats. Comb. Chem. High Throughput Screen 2021 :6152320 . 10.2174/1386207324666210506152320 33966617
Liu X. K. Wang G. Chen S. D. (2010). Modulation of the activity of dopaminergic neurons by SK channels: a potential target for the treatment of Parkinson’s disease? Neurosci. Bull. 26 265–271. 10.1007/s12264-010-1217-4 20502506
Liu Y. Hao S. Yang B. Fan Y. Qin X. Chen Y. (2017). Wnt/beta-catenin signaling plays an essential role in alpha7 nicotinic receptor-mediated neuroprotection of dopaminergic neurons in a mouse Parkinson’s disease model. Biochem. Pharmacol. 140 115–123. 10.1016/j.bcp.2017.05.017 28551099
Livingstone P. D. Wonnacott S. (2009). Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol. 78 744–755.19523928
Lohle M. Hermann W. Hausbrand D. Wolz M. Mende J. Beuthien-Baumann B. (2019). Putaminal dopamine turnover in de novo parkinson’s disease predicts later neuropsychiatric fluctuations but not other major health outcomes. J. Parkinsons. Dis. 9 693–704. 10.3233/JPD-191672 31381528
Lopes E. F. Roberts B. M. Siddorn R. E. Clements M. A. Cragg S. J. (2019). Inhibition of nigrostriatal dopamine release by striatal GABAA and GABAB Receptors. J. Neurosci. 39 1058–1065. 10.1523/JNEUROSCI.2028-18.2018 30541909
Lu J. Cheng Y. Xie X. Woodson K. Bonifacio J. Disney E. (2021). Whole-brain mapping of direct inputs to dopamine D1 and D2 Receptor-expressing medium spiny neurons in the posterior dorsomedial striatum. eNeuro 8 :2020 . 10.1523/ENEURO.0348-20.2020 33380525
Lu J. Wu W. (2021). Cholinergic modulation of the immune system - A novel therapeutic target for myocardial inflammation. Int. Immunopharmacol. 93 :107391 . 10.1016/j.intimp.2021.107391 33548577
Lu X. Cui Z. Liu S. Yin F. (2018). MiRNAs participate in the diagnosis, pathogenesis and therapy of Parkinson’s disease. Histol. Histopathol. 33 447–453. 10.14670/HH-11-944 29135019
Lu X. Kim-Han J. S. Harmon S. Sakiyama-Elbert S. E. O’Malley K. L. (2014). The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol. Neurodegener. 9 :17 . 10.1186/1750-1326-9-17 24885281
Luo R. Janssen M. J. Partridge J. G. Vicini S. (2013). Direct and GABA-mediated indirect effects of nicotinic ACh receptor agonists on striatal neurones. J. Physiol. 591 203–217. 10.1113/jphysiol.2012.241786 23045343
Lykhmus O. Gergalova G. Koval L. Zhmak M. Komisarenko S. Skok M. (2014). Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathways of apoptosis induction. Int. J. Biochem. Cell. Biol. 53 246–252. 10.1016/j.biocel.2014.05.030 24880090
Maggio R. Riva M. Vaglini F. Fornai F. Molteni R. Armogida M. (1998). Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71 2439–2446. 10.1046/j.1471-4159.1998.71062439.x 9832142
Maillet A. Krack P. Lhommee E. Metereau E. Klinger H. Favre E. (2016). The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139 (Pt 9 ), 2486–2502. 10.1093/brain/aww162 27538418
Majdi A. Kamari F. Sadigh-Eteghad S. Gjedde A. (2018). Molecular insights into memory-enhancing metabolites of nicotine in brain: a systematic review. Front. Neurosci. 12 :1002 . 10.3389/fnins.2018.01002 30697142
Mallet N. Leblois A. Maurice N. Beurrier C. (2019). Striatal cholinergic interneurons: how to elucidate their function in health and disease. Front. Pharmacol. 10 :1488 . 10.3389/fphar.2019.01488 31920670
Mappin-Kasirer B. Pan H. Lewington S. Kizza J. Gray R. Clarke R. (2020). Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors. Neurology 94 e2132–e2138. 10.1212/WNL.0000000000009437 32371450
Marchetti B. (2018). Wnt/beta-catenin signaling pathway governs a full program for dopaminergic neuron survival, neurorescue and regeneration in the mptp mouse model of parkinson’s disease. Int. J. Mol. Sci. 19 :19123743 . 10.3390/ijms19123743 30477246
Marchi M. Risso F. Viola C. Cavazzani P. Raiteri M. (2002). Direct evidence that release-stimulating alpha7∗ nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J. Neurochem. 80 1071–1078. 10.1046/j.0022-3042.2002.00805.x 11953457
Marshall D. L. Redfern P. H. Wonnacott S. (1997). Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem. 68 1511–1519. 10.1046/j.1471-4159.1997.68041511.x 9084421
Martel A. C. Apicella P. (2021). Temporal processing in the striatum: Interplay between midbrain dopamine neurons and striatal cholinergic interneurons. Eur. J. Neurosci. 53 2090–2099. 10.1111/ejn.14741 32281157
Martin Z. S. Neugebauer V. Dineley K. T. Kayed R. Zhang W. Reese L. C. (2012). alpha-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J. Neurochem. 120 440–452. 10.1111/j.1471-4159.2011.07576.x 22060133
Martinez-Banaclocha M. (2021). Proteomic Complexity in Parkinson’s Disease: A Redox Signaling Perspective of the Pathophysiology and Progression. Neuroscience 453 287–300. 10.1016/j.neuroscience.2020.11.006 33212217
Martin-Jimenez C. A. Gaitan-Vaca D. M. Echeverria V. Gonzalez J. Barreto G. E. (2017). Relationship between obesity, alzheimer’s disease, and parkinson’s disease: an astrocentric view. Mol. Neurobiol. 54 7096–7115. 10.1007/s12035-016-0193-8 27796748
Mashimo M. Fujii T. Ono S. Moriwaki Y. Misawa H. Kawashima K. (2020). Minireview: Divergent roles of alpha7 nicotinic acetylcholine receptors expressed on antigen-presenting cells and CD4(+) T cells in the regulation of T cell differentiation. Int. Immunopharmacol. 82 :106306 . 10.1016/j.intimp.2020.106306 32086096
Mathur B. N. Lovinger D. M. (2012). Serotonergic action on dorsal striatal function. Parkinsonism Relat. Disord. 18 (Suppl. 1 ), S129–S131. 10.1016/S1353-8020(11)70040-2 22166410
Maurice N. Liberge M. Jaouen F. Ztaou S. Hanini M. Camon J. (2015). Striatal Cholinergic interneurons control motor behavior and basal ganglia function in experimental parkinsonism. Cell Rep. 13 657–666. 10.1016/j.celrep.2015.09.034 26489458
McCarthy M. M. Moore-Kochlacs C. Gu X. Boyden E. S. Han X. Kopell N. (2011). Striatal origin of the pathologic beta oscillations in Parkinson’s disease. Proc. Natl. Acad. Sci. U S A 108 11620–11625. 10.1073/pnas.1107748108 21697509
McKinley J. W. Shi Z. Kawikova I. Hur M. Bamford I. J. Sudarsana Devi S. P. (2019). Dopamine deficiency reduces striatal cholinergic interneuron function in models of parkinson’s disease. Neuron 105 :e1056 . 10.1016/j.neuron.2019.06.013 31324539
Mehra S. Sahay S. Maji S. K. (2019). alpha-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis. Biochim. Biophys. Acta Proteins Proteom. 1867 890–908. 10.1016/j.bbapap.2019.03.001 30853581
Mendonca I. P. Duarte-Silva E. Chaves-Filho A. J. M. Andrade, da Costa B. Peixoto C. A. (2020). Neurobiological findings underlying depressive behavior in Parkinson’s disease: A review. Int. Immunopharmacol. 83 :106434 . 10.1016/j.intimp.2020.106434 32224442
Mendoza C. Perez-Urrutia N. Alvarez-Ricartes N. Barreto G. E. Perez-Ordas R. Iarkov A. (2018). Cotinine plus krill oil decreased depressive behavior, and increased astrocytes survival in the hippocampus of mice subjected to restraint stress. Front. Neurosci. 12 :952 . 10.3389/fnins.2018.00952 30618579
Mesulam M. M. Mash D. Hersh L. Bothwell M. Geula C. (1992). Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus. J. Comp. Neurol. 323 252–268. 10.1002/cne.903230209 1401259
Mesulam M. M. Mufson E. J. Levey A. I. Wainer B. H. (1983). Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 214 170–197. 10.1002/cne.902140206 6841683
Mihailescu S. Drucker-Colin R. (2000). Nicotine and brain disorders. Acta Pharmacol. Sin. 21 97–104.11263271
Miklossy J. Steele J. C. Yu S. McCall S. Sandberg G. McGeer E. G. (2008). Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol. 116 625–637.18843496
Millar N. S. (2003). Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem. Soc. Trans. 31 (Pt 4 ), 869–874. 10.1042/bst0310869 12887324
Millar N. S. Gotti C. (2009). Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 56 237–246. 10.1016/j.neuropharm.2008.07.041 18723036
Moran V. E. (2012). Cotinine: beyond that expected. more than a biomarker of tobacco consumption. Front. Pharmacol. 3 173 .
Morelli M. Carta A. R. Kachroo A. Schwarzschild M. A. (2010). Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 183 183–208. 10.1016/S0079-6123(10)83010-9 20696321
Moreno E. Hoffmann H. Gonzalez-Sepulveda M. Navarro G. Casado V. Cortes A. (2011). Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J. Biol. Chem. 286 5846–5854. 10.1074/jbc.M110.161489 21173143
Morioka N. Hisaoka-Nakashima K. Nakata Y. (2018). “Regulation by Nicotinic Acetylcholine Receptors of Microglial Glutamate Transporters: Role of Microglia in Neuroprotection,” in Nicotinic Acetylcholine Receptor Signaling in Neuroprotection, eds Akaike A. Shimohama S. Misu Y. (Singapore: Springer), 73–88.
Morioka N. Tokuhara M. Nakamura Y. Idenoshita Y. Harano S. Zhang F. F. (2014). Primary cultures of rat cortical microglia treated with nicotine increases in the expression of excitatory amino acid transporter 1 (GLAST) via the activation of the alpha7 nicotinic acetylcholine receptor. Neuroscience 258 374–384. 10.1016/j.neuroscience.2013.11.044 24300109
Morishima S. Anisuzzaman A. S. M. Uwada J. Yoshiki H. Muramatsu I. (2013). Comparison of subcellular distribution and functions between exogenous and endogenous M1 muscarinic acetylcholine receptors. Life Sci. 93 17–23. 10.1016/j.lfs.2013.05.013 23727356
Mudo G. Belluardo N. Fuxe K. (2007). Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J. Neural. Transm. 114 135–147. 10.1007/s00702-006-0561-z 16906354
Munoz-Manchado A. B. Bengtsson Gonzales C. Zeisel A. Munguba H. Bekkouche B. Skene N. G. (2018). Diversity of interneurons in the dorsal striatum revealed by single-cell RNA Sequencing and PatchSeq. Cell Rep. 217 :e2177 . 10.1016/j.celrep.2018.07.053 30134177
Muramatsu I. Masuoka T. Uwada J. Yoshiki H. Yazama T. Lee K.-S. (2018). “A New Aspect of Cholinergic Transmission in the Central Nervous System,” in Nicotinic Acetylcholine Receptor Signaling in Neuroprotection, eds Akaike A. Shimohama S. Misu Y. (Singapore: Springer), 45–58.
Myslivecek J. (2021). Two players in the field: hierarchical model of interaction between the dopamine and acetylcholine signaling systems in the striatum. Biomedicines 9 :25 . 10.3390/biomedicines9010025 33401461
Myslivecek J. Farar V. Valuskova P. (2017). M(4) muscarinic receptors and locomotor activity regulation. Physiol. Res. 66 (Suppl. 4 ), S443–S455. 10.33549/physiolres.933796 29355372
Nees F. (2015). The nicotinic cholinergic system function in the human brain. Neuropharmacology 96 289–301. 10.1016/j.neuropharm.2014.10.021 25446570
O’Callaghan J. P. Miller D. B. (2019). Neuroinflammation disorders exacerbated by environmental stressors. Metabolism 100S :153951 . 10.1016/j.metabol.2019.153951 31610852
Olanow C. W. Tatton W. G. (1999). Etiology and pathogenesis of Parkinson’s disease. Annu. Rev. Neurosci. 22 123–144. 10.1146/annurev.neuro.22.1.123 10202534
Oldan J. D. Jewells V. L. Pieper B. Wong T. Z. (2021). Complete evaluation of dementia: PET and MRI Correlation and diagnosis for the neuroradiologist. AJNR Am. J. Neuroradiol. 2021 :7079 . 10.3174/ajnr.A7079 33926896
Oldenburg I. A. Ding J. B. (2011). Cholinergic modulation of synaptic integration and dendritic excitability in the striatum. Curr. Opin. Neurobiol. 21 425–432. 10.1016/j.conb.2011.04.004 21550798
O’Leary K. Parameswaran N. McIntosh J. M. Quik M. (2008). Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J. Pharmacol. Exp. Ther. 325 646–654. 10.1124/jpet.108.136838 18305015
Oliveros-Matus P. Perez-Urrutia N. Alvarez-Ricartes N. Echeverria F. Barreto G. E. Elliott J. (2020). Cotinine enhances fear extinction and astrocyte survival by mechanisms involving the nicotinic acetylcholine receptors signaling. Front. Pharmacol. 11 :303 . 10.3389/fphar.2020.00303 32300297
Oorschot D. E. (1996). Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J. Comp. Neurol. 580–599. 10.1002/(SICI)1096-9861(19960318)366:4<580::AID-CNE3<3.0.CO;2-0 8833111
Osada O. Iwasaki A. (2017). A case of successful treatment with donepezil of olfactory hallucination in parkinson disease. Rinsho Shinkeigaku 57 29–32. 10.5692/clinicalneurol.cn-000913 27980286
Owens-Walton C. Jakabek D. Power B. D. Walterfang M. Hall S. van Westen D. (2021). Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease. Psychiatry Res. Neuroimag. 312 :111273 . 10.1016/j.pscychresns.2021.111273 33892387
Pakhotin P. Bracci E. (2007). Cholinergic interneurons control the excitatory input to the striatum. J. Neurosci. 27 391–400. 10.1523/JNEUROSCI.3709-06.2007 17215400
Palermo G. Frosini D. Corsi A. Giuntini M. Mazzucchi S. Del Prete E. (2019a). Freezing of gait and dementia in parkinsonism: a retrospective case-control study. Brain Behav. 9 :e01247 . 10.1002/brb3.1247 31074064
Palermo G. Tommasini L. Aghakhanyan G. Frosini D. Giuntini M. Tognoni G. (2019b). Clinical correlates of cerebral amyloid deposition in parkinson’s disease dementia: evidence from a PET Study. J. Alzheimers Dis. 70 597–609. 10.3233/JAD-190323 31256138
Papke R. L. Lindstrom J. M. (2020). Nicotinic acetylcholine receptors: Conventional and unconventional ligands and signaling. Neuropharmacology 168 :108021 . 10.1016/j.neuropharm.2020.108021 32146229
Parain K. Hapdey C. Rousselet E. Marchand V. Dumery B. Hirsch E. C. (2003). Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 984 224–232.12932857
Parain K. Marchand V. Dumery B. Hirsch E. (2001). Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. Brain Res. 890 347–350.11164803
Parent M. Wallman M. J. Gagnon D. Parent A. (2011). Serotonin innervation of basal ganglia in monkeys and humans. J. Chem. Neuroanat. 41 256–265. 10.1016/j.jchemneu.2011.04.005 21664455
Park H. J. Lee P. H. Ahn Y. W. Choi Y. J. Lee G. Lee D. Y. (2007). Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci. 26 79–89. 10.1111/j.1460-9568.2007.05636.x 17581257
Patel S. Grizzell J. A. Holmes R. Zeitlin R. Solomon R. Sutton T. L. (2014). Cotinine halts the advance of Alzheimer’s disease-like pathology and associated depressive-like behavior in Tg6799 mice. Front. Aging Neurosci. 6 :162 . 10.3389/fnagi.2014.00162 25100990
Patt S. Gertz H. J. Gerhard L. Cervos-Navarro J. (1991). Pathological changes in dendrites of substantia nigra neurons in Parkinson’s disease: a Golgi study. Histol. Histopathol. 6 373–380.1725760
Pavlou M. A. S. Outeiro T. F. (2017). Epigenetics in Parkinson’s Disease. Adv. Exp. Med. Biol. 978 363–390. 10.1007/978-3-319-53889-1_19 28523556
Perez M. J. Jara C. Quintanilla R. A. (2018). Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration. Front. Neurosci. 12 :441 . 10.3389/fnins.2018.00441 30026680
Perier C. Vila M. (2012). Mitochondrial biology and Parkinson’s disease. Cold Spring Harb. Perspect. Med. 2 :a009332 . 10.1101/cshperspect.a009332 22355801
Phelps P. E. Houser C. R. Vaughn J. E. (1985). Immunocytochemical localization of choline acetyltransferase within the rat neostriatum: a correlated light and electron microscopic study of cholinergic neurons and synapses. J. Comp. Neurol. 238 286–307. 10.1002/cne.902380305 4044917
Picciotto M. R. Caldarone B. J. King S. L. Zachariou V. (2000). Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22 451–465.10731620
Picciotto M. R. Higley M. J. Mineur Y. S. (2012). Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron 76 116–129. 10.1016/j.neuron.2012.08.036 23040810
Pillai S. Chellappan S. (2012). alpha7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. Curr. Drug Targets 13 671–679.22300034
Pimlott S. L. Piggott M. Owens J. Greally E. Court J. A. Jaros E. (2004). Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 29 108–116. 10.1038/sj.npp.1300302 12955099
Pisani A. Bonsi P. Centonze D. Calabresi P. Bernardi G. (2000). Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J. Neurosci. 20 :RC69 .
Poewe W. Seppi K. Tanner C. M. Halliday G. M. Brundin P. Volkmann J. (2017). Parkinson disease. Nat. Rev. Dis. Primers 3 :17013 . 10.1038/nrdp.2017.13 28332488
Pogocki D. Ruman T. Danilczuk M. Danilczuk M. Celuch M. Walajtys-Rode E. (2007). Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. Eur. J. Pharmacol. 563 18–39.17376429
Pohanka M. (2021). Pharmacological Influencing of The Cholinergic Anti-inflammatory pathway in infectious diseases and inflammatory pathologies. Mini. Rev. Med. Chem. 21 660–669. 10.2174/1389557520666201117111715 33208075
Prots I. Grosch J. Brazdis R. M. Simmnacher K. Veber V. Havlicek S. (2018). alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc. Natl. Acad. Sci. U S A 115 7813–7818. 10.1073/pnas.1713129115 29991596
Prots I. Veber V. Brey S. Campioni S. Buder K. Riek R. (2013). alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288 21742–21754. 10.1074/jbc.M113.451815 23744071
Przuntek H. Muller T. (1999). Clinical efficacy of budipine in Parkinson’s disease. J. Neural. Transm. Suppl. 56 75–82. 10.1007/978-3-7091-6360-3_3 10370903
Quik M. (2004). Smoking, nicotine and Parkinson’s disease. Trends Neurosci. 27 561–568. 10.1016/j.tins.2004.06.008 15331239
Quik M. Bordia T. Huang L. Perez X. (2011). Targeting nicotinic receptors for Parkinson’s disease therapy. CNS Neurol. Disord Drug Targets 10 651–658.21838678
Quik M. Bordia T. O’Leary K. (2007). Nicotinic receptors as CNS targets for Parkinson’s disease. Biochem, Pharmacol. 74 1224–1234. 10.1016/j.bcp.2007.06.015 17631864
Quik M. Bordia T. Zhang D. Perez X. A. (2015a). Nicotine and Nicotinic Receptor Drugs: Potential for Parkinson’s Disease and Drug-Induced Movement Disorders. Int. Rev. Neurobiol. 124 247–271. 10.1016/bs.irn.2015.07.005 26472532
Quik M. Campos C. Grady S. R. (2013a). Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice. Biochem. Pharmacol. 86 1153–1162. 10.1016/j.bcp.2013.06.027 23831952
Quik M. Huang L. Z. Parameswaran N. Bordia T. Campos C. Perez X. A. (2009). Multiple roles for nicotine in Parkinson’s disease. Biochem. Pharmacol. 78 677–685. 10.1016/j.bcp.2009.05.003 19433069
Quik M. Kulak J. M. (2002). Nicotine and nicotinic receptors; relevance to Parkinson’s disease. Neurotoxicology 23 581–594.12428730
Quik M. Mallela A. Ly J. Zhang D. (2013b). Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson’s disease. Mov. Disord 28 1398–1406. 10.1002/mds.25594 23836409
Quik M. McIntosh J. M. (2006). Striatal alpha6∗ nicotinic acetylcholine receptors: potential targets for Parkinson’s disease therapy. J. Pharmacol. Exp. Ther. 316 481–489. 10.1124/jpet.105.094375 16210393
Quik M. Parameswaran N. McCallum S. E. Bordia T. Bao S. McCormack A. (2006). Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98 1866–1875. 10.1111/j.1471-4159.2006.04078.x 16882311
Quik M. Park K. M. Hrachova M. Mallela A. Huang L. Z. McIntosh J. M. (2012). Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63 450–459. 10.1016/j.neuropharm.2012.04.029 22579614
Quik M. Wonnacott S. (2011). alpha6beta2∗ and alpha4beta2∗ nicotinic acetylcholine receptors as drug targets for Parkinson’s disease. Pharmacol. Rev. 63 938–966. 10.1124/pr.110.003269 21969327
Quik M. Zhang D. McGregor M. Bordia T. (2015b). Alpha7 nicotinic receptors as therapeutic targets for Parkinson’s disease. Biochem. Pharmacol. 97 399–407. 10.1016/j.bcp.2015.06.014 26093062
Quirion R. Aubert I. Robitaille Y. Gauthier S. Araujo D. M. Chabot J. G. (1990). Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies. Clin. Neuropharmacol. 13 (Suppl. 3 ), S73–S80.2093419
Rajmohan R. Reddy P. H. (2017). Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of alzheimer’s disease neurons. J. Alzheimers. Dis. 57 975–999. 10.3233/JAD-160612 27567878
Reader T. A. Dewar K. M. (1999). Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum: implications for human Parkinson’s disease. Neurochem. Int. 34 1–21. 10.1016/s0197-0186(98)00048-5 10100192
Rehani K. Scott D. A. Renaud D. Hamza H. Williams L. R. Wang H. (2008). Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim. Biophys. Acta 1783 375–382.18178163
Rehman S. Dimri M. (2020). Biochemistry, G Protein Coupled Receptors. Treasure Island, FL: StatPearls.
Reich S. G. Savitt J. M. (2019). Parkinson’s Disease. Med. Clin. North Am. 103 337–350. 10.1016/j.mcna.2018.10.014 30704685
Renouf S. Ffytche D. Pinto R. Murray J. Lawrence V. (2018). Visual hallucinations in dementia and Parkinson’s disease: a qualitative exploration of patient and caregiver experiences. Int. J. Geriatr. Psychiatry 33 1327–1334. 10.1002/gps.4929 29953689
Requejo-Aguilar R. Bolanos J. P. (2016). Mitochondrial control of cell bioenergetics in Parkinson’s disease. Free Radic. Biol. Med. 100 123–137. 10.1016/j.freeradbiomed.2016.04.012 27091692
Resende R. R. Adhikari A. (2009). Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation. Cell Commun. Signal. 7 :20 . 10.1186/1478-811X-7-20 19712465
Riveles K. Huang L. Z. Quik M. (2008). Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. Neurotoxicology 29 421–427.18359086
Rizzi G. Tan K. R. (2017). Dopamine and Acetylcholine, a Circuit Point of View in Parkinson’s Disease. Front. Neural. Circuits 11 :110 . 10.3389/fncir.2017.00110 29311846
Robinson L. Platt B. Riedel G. (2011). Involvement of the cholinergic system in conditioning and perceptual memory. Behav. Brain Res. 221 443–465. 10.1016/j.bbr.2011.01.055 21315109
Rodriguez-Sabate C. Rodriguez M. Morales I. (2021). Studying the functional connectivity of the primary motor cortex with the binarized cross recurrence plot: The influence of Parkinson’s disease. PLoS One 16 :e0252565 . 10.1371/journal.pone.0252565 34097691
Roselli F. Pisciotta N. M. Pennelli M. Aniello M. S. Gigante A. De Caro M. F. (2010). Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov. Disord. 25 1853–1859. 10.1002/mds.23179 20669272
Ross H. F. Hughes T. A. Boyd J. L. Biggins C. A. Madeley P. Mindham R. H. (1996). The evolution and profile of dementia in Parkinson’s disease. Adv. Neurol. 69 343–347.8615150
Roth B. L. (2019). Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. Nat. Struct. Mol. Biol. 26 535–544. 10.1038/s41594-019-0252-8 31270468
Sadigh-Eteghad S. Vatandoust S. M. Mahmoudi J. Rahigh Aghsan S. Majdi A. (2020). Cotinine ameliorates memory and learning impairment in senescent mice. Brain Res. Bull. 164 65–74. 10.1016/j.brainresbull.2020.08.010 32818583
Saitgareeva A. R. Bulygin K. V. Gareev I. F. Beylerli O. A. Akhmadeeva L. R. (2020). The role of microglia in the development of neurodegeneration. Neurol. Sci. 41 3609–3615. 10.1007/s10072-020-04468-5 32458252
Salminen O. Seppa T. Gaddnas H. Ahtee L. (1999). The effects of acute nicotine on the metabolism of dopamine and the expression of Fos protein in striatal and limbic brain areas of rats during chronic nicotine infusion and its withdrawal. J. Neurosci. 19 8145–8151.10479714
Samudra N. Patel N. Womack K. B. Khemani P. Chitnis S. (2016). Psychosis in parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging 33 855–863. 10.1007/s40266-016-0416-8 27830568
Sanjari Moghaddam H. Zare-Shahabadi A. Rahmani F. Rezaei N. (2017). Neurotransmission systems in Parkinson’s disease. Rev. Neurosci. 28 509–536. 10.1515/revneuro-2016-0068 28328536
Santiago L. J. Abrol R. (2019). Understanding G Protein selectivity of muscarinic acetylcholine receptors using computational methods. Int. J. Mol. Sci. 20 :20215290 . 10.3390/ijms20215290 31653051
Sastry B. V. (1995). Neuropharmacology of nicotine: effects on the autoregulation of acetylcholine release by substance P and methionine enkephalin in rodent cerebral slices and toxicological implications. Clin. Exp. Pharmacol. Physiol. 22 288–290.7545560
Sato K. Z. Fujii T. Watanabe Y. Yamada S. Ando T. Kazuko F. (1999). Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci. Lett. 266 17–20. 10.1016/s0304-3940(99)00259-1 10336173
Sayas C. L. Avila J. (2021). GSK-3 and tau: a key duet in alzheimer’s disease. Cells 10 :721 . 10.3390/cells10040721 33804962
Schapira A. H. (2011). Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs 25 1061–1071. 10.2165/11596310-000000000-00000 22133327
Schapira A. H. Jenner P. (2011). Etiology and pathogenesis of Parkinson’s disease. Mov. Disord 26 1049–1055. 10.1002/mds.23732 21626550
Schulz-Schaeffer W. J. (2010). The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol. 120 131–143. 10.1007/s00401-010-0711-0 20563819
Schulz-Schaeffer W. J. (2015). Is cell death primary or secondary in the pathophysiology of idiopathic parkinson’s disease? Biomolecules 5 1467–1479. 10.3390/biom5031467 26193328
Scott L. Dawson V. L. Dawson T. M. (2017). Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson’s disease genes. Exp. Neurol. 298 191–201. 10.1016/j.expneurol.2017.04.008 28445716
Searles Nielsen S. Gallagher L. G. Lundin J. I. Longstreth W. T. Jr. Smith-Weller T. Franklin G. M. (2012). Environmental tobacco smoke and Parkinson’s disease. Mov. Disord. 27 293–296. 10.1002/mds.24012 22095755
Shamoto-Nagai M. Hisaka S. Naoi M. Maruyama W. (2018). Modification of alpha-synuclein by lipid peroxidation products derived from polyunsaturated fatty acids promotes toxic oligomerization: its relevance to Parkinson disease. J. Clin. Biochem. Nutr. 62 207–212. 10.3164/jcbn.18-25 29892158
Sharma P. K. Wells L. Rizzo G. Elson J. L. Passchier J. Rabiner E. A. (2020). DREADD activation of pedunculopontine cholinergic neurons reverses motor deficits and restores striatal dopamine signaling in parkinsonian rats. Neurotherapeutics 17 1120–1141. 10.1007/s13311-019-00830-4 31965550
Shimohama S. Kawamata J. (2018). “Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer’s and Parkinson’s Diseases,” in Nicotinic Acetylcholine Receptor Signaling in Neuroprotection, eds Akaike A. Shimohama S. Misu Y. (Singapore: Springer), 137–158.
Shin N. Y. Bang M. Yoo S. W. Kim J. S. Yun E. Yoon U. (2021). Cortical thickness from mri to predict conversion from mild cognitive impairment to dementia in parkinson disease: a machine learning-based model. Radiology 2021 :203383 . 10.1148/radiol.2021203383 34032515
Siciliano C. A. McIntosh J. M. Jones S. R. Ferris M. J. (2017). alpha6beta2 subunit containing nicotinic acetylcholine receptors exert opposing actions on rapid dopamine signaling in the nucleus accumbens of rats with high-versus low-response to novelty. Neuropharmacology 126 281–291. 10.1016/j.neuropharm.2017.06.028 28666811
Sil’kis I. G. (2003). [The influence of neuromodulators on the synaptic plasticity in dopaminergic structures of the midbrain (hypothetical mechanism)]. Zh Vyssh Nerv Deiat Im I P Pavlova 53 464–479.14598554
Singh J. Singh P. Malik V. (2017). Sensitivity analysis of discharge patterns of subthalamic nucleus in the model of basal ganglia in Parkinson disease. J. Integr. Neurosci. 16 441–452. 10.3233/JIN-170027 28891523
Skok M. Lykhmus O. (2016). The Role of alpha7 nicotinic acetylcholine receptors and alpha7-specific antibodies in neuroinflammation related to alzheimer disease. Curr. Pharm. Des. 22 2035–2049. 10.2174/1381612822666160127112914 26818865
Skok M. V. Kalashnik E. N. Koval L. N. Tsetlin V. I. Utkin Y. N. Changeux J. P. (2003). Functional nicotinic acetylcholine receptors are expressed in B lymphocyte-derived cell lines. Mol. Pharmacol. 64 885–889. 10.1124/mol.64.4.885 14500745
Snijders A. H. Takakusaki K. Debu B. Lozano A. M. Krishna V. Fasano A. (2016). Physiology of freezing of gait. Ann. Neurol. 80 644–659. 10.1002/ana.24778 27649270
Soto-Otero R. Mendez-Alvarez E. Hermida-Ameijeiras A. Lopez-Real A. M. Labandeira-Garcia J. L. (2002). Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson’s disease. Biochem. Pharmacol. 64 125–135. 10.1016/s0006-2952(02)01070-5 12106613
Srinivasan R. Pantoja R. Moss F. J. Mackey E. D. Son C. D. Miwa J. (2011). Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. J. Gen. Physiol. 137 59–79. 10.1085/jgp.201010532 21187334
Srivareerat M. Tran T. T. Salim S. Aleisa A. M. Alkadhi K. A. (2011). Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer’s disease. Neurobiol. Aging 32 834–844. 10.1016/j.neurobiolaging.2009.04.015 19464074
Stein J. F. Aziz T. Z. (2012). Basal ganglia output to the PPN, a commentary. Exp. Neurol. 233 745–746. 10.1016/j.expneurol.2011.11.023 22134154
Steinberg R. Souilhac J. Rodier D. Alonso R. Emonds-Alt X. Le Fur G. (1998). Facilitation of striatal acetylcholine release by dopamine D1 receptor stimulation: involvement of enhanced nitric oxide production via neurokinin-2 receptor activation. Neuroscience 84 511–518. 10.1016/s0306-4522(97)00558-7 9539221
Stone T. W. (2021). Relationships and interactions between ionotropic glutamate receptors and nicotinic receptors in the CNS. Neuroscience 2021 :7 . 10.1016/j.neuroscience.2021.06.007 34111447
Stoof J. C. Drukarch B. de Boer P. Westerink B. H. (1992). In vitro and in vivo acetylcholine release from rat striatum as a functional paradigm of signal transduction via a D-2 dopamine receptor. Neurochem. Int. 20 201S–205S. 10.1016/0197-0186(92)90239-n 1365426
Subramaniam S. R. Chesselet M. F. (2013). Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog. Neurobiol. 10 17–32. 10.1016/j.pneurobio.2013.04.004 23643800
Sudheer P. S. Hall J. E. Donev R. Read G. Rowbottom A. Williams P. E. (2006). Nicotinic acetylcholine receptors on basophils and mast cells. Anaesthesia 61 1170–1174. 10.1111/j.1365-2044.2006.04870.x 17090238
Sulzer D. (2007). Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 30 244–250. 10.1016/j.tins.2007.03.009 17418429
Sulzer D. Schmitz Y. (2007). Parkinson’s disease: return of an old prime suspect. Neuron 55 8–10. 10.1016/j.neuron.2007.06.023 17610813
Surmeier D. J. Graybiel A. M. (2012). A feud that wasn’t: acetylcholine evokes dopamine release in the striatum. Neuron 75 1–3. 10.1016/j.neuron.2012.06.028 22794253
Sutachan J. J. Casas Z. Albarracin S. L. Stab B. R. II Samudio I. Gonzalez J. (2012). Cellular and molecular mechanisms of antioxidants in Parkinson’s disease. Nutr. Neurosci. 15 120–126. 10.1179/1476830511Y.0000000033 22732354
Takahashi M. Yamada T. (1999). Viral etiology for Parkinson’s disease–a possible role of influenza A virus infection. JPNJ. Infect. Dis. 52 89–98.
Takahashi T. (2020). Roles of nAChR and Wnt signaling in intestinal stem cell function and inflammation. Int. Immunopharmacol. 81 :106260 . 10.1016/j.intimp.2020.106260 32007796
Tanaka K. Miyake Y. Fukushima W. Sasaki S. Kiyohara C. Tsuboi Y. (2010). Active and passive smoking and risk of Parkinson’s disease. Acta Neurol. Scand. 122 377–382. 10.1111/j.1600-0404.2010.01327.x 20175761
Tanimura A. Pancani T. Lim S. A. O. Tubert C. Melendez A. E. Shen W. (2018). Striatal cholinergic interneurons and Parkinson’s disease. Eur. J. Neurosci. 47 1148–1158. 10.1111/ejn.13638 28677242
Tata A. M. Velluto L. D’Angelo C. Reale M. (2014). Cholinergic system dysfunction and neurodegenerative diseases: cause or effect? CNS Neurol. Disord. Drug Targets 13 1294–1303. 10.2174/1871527313666140917121132 25230223
Taverna S. Ilijic E. Surmeier D. J. (2008). Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson’s disease. J. Neurosci. 28 5504–5512. 10.1523/JNEUROSCI.5493-07.2008 18495884
Tepper J. M. Abercrombie E. D. Bolam J. P. (2007). Basal ganglia macrocircuits. Prog. Brain. Res. 160 3–7. 10.1016/S0079-6123(06)60001-0 17499105
Terenzi M. G. Rees H. Roberts M. H. (1992). The pontine parabrachial region mediates some of the descending inhibitory effects of stimulating the anterior pretectal nucleus. Brain Res. 594 205–214. 10.1016/0006-8993(92)91127-z 1450946
Terry A. V. Jr. Buccafusco J. J. Schade R. F. Vandenhuerk L. Callahan P. M. Beck W. D. (2012). The nicotine metabolite, cotinine, attenuates glutamate (n.d.) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem. Pharmacol. 83 941–951.22244928
Terry A. V. Jr. Callahan P. M. Bertrand D. (2015). R-(+) and s-(-) isomers of cotinine augment cholinergic responses in vitro and in vivo. J. Pharmacol. Exp. Ther. 352 405–418.25503389
Terry A. V. Jr. Hernandez C. M. Hohnadel E. J. Bouchard K. P. Buccafusco J. J. (2005). Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev. 11 229–252.16389292
Thomas B. Beal M. F. (2007). Parkinson’s disease. Hum. Mol. Genet. 2 R183–R194. 10.1093/hmg/ddm159 17911161
Thomas R. L. Langmead C. J. Wood M. D. Challiss R. A. (2009). Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation. J. Pharmacol. Exp. Ther. 331 1086–1095. 10.1124/jpet.109.160242 19767446
Thomopoulos C. Lombardi C. Parati G. (2013). Cotinine and blood pressure levels: variability omitted once again. Hypertension 61 :e41 . 10.1161/HYPERTENSIONAHA.111.00812 23424233
Threlfell S. Clements M. A. Khodai T. Pienaar I. S. Exley R. Wess J. (2010). Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J. Neurosci. 30 3398–3408. 10.1523/JNEUROSCI.5620-09.2010 20203199
Threlfell S. Cragg S. J. (2011). Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. Front. Syst. Neurosci. 5 :11 . 10.3389/fnsys.2011.00011 21427783
Threlfell S. Lalic T. Platt N. J. Jennings K. A. Deisseroth K. Cragg S. J. (2012). Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75 58–64. 10.1016/j.neuron.2012.04.038 22794260
Titova N. Chaudhuri K. R. (2018). Non-motor Parkinson disease: new concepts and personalised management. Med. J. Aust. 208 404–409.29764353
Tiwari M. N. Agarwal S. Bhatnagar P. Singhal N. K. Tiwari S. K. Kumar P. (2013). Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic. Biol. Med. 65 704–718. 10.1016/j.freeradbiomed.2013.07.042 23933227
Tiwari M. N. Agarwal S. Bhatnagar P. Singhal N. K. Tiwari S. K. Kumar P. (2015). Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic. Biol. Med. 65 704–718.
Tobin A. B. Budd D. C. (2003). The anti-apoptotic response of the Gq/11-coupled muscarinic receptor family. Biochem. Soc. Trans. 31 (Pt 6 ), 1182–1185. 10.1042/bst0311182 14641022
Tompkins M. M. Basgall E. J. Zamrini E. Hill W. D. (1997). Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150 119–131.9006329
Toulorge D. Guerreiro S. Hild A. Maskos U. Hirsch E. C. Michel P. P. (2011). Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J. 25 2563–2573. 10.1096/fj.11-182824 21507900
Tozzi A. de Iure A. Di Filippo M. Tantucci M. Costa C. Borsini F. (2011). The distinct role of medium spiny neurons and cholinergic interneurons in the D(2)/A(2)A receptor interaction in the striatum: implications for Parkinson’s disease. J. Neurosci. 31 1850–1862. 10.1523/JNEUROSCI.4082-10.2011 21289195
Tripathy D. Chakraborty J. Mohanakumar K. P. (2015). Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson’s disease. Free Radic Res. 49 1129–1139. 10.3109/10715762.2015.1045505 25968946
Uspenska K. Lykhmus O. Gergalova G. Chernyshov V. Arias H. R. Komisarenko S. (2017). Nicotine facilitates nicotinic acetylcholine receptor targeting to mitochondria but makes them less susceptible to selective ligands. Neurosci. Lett. 656 43–50. 10.1016/j.neulet.2017.07.009 28700952
Uwada J. Yoshiki H. Masuoka T. Nishio M. Muramatsu I. (2014). Intracellular localization of the M1 muscarinic acetylcholine receptor through clathrin-dependent constitutive internalization is mediated by a C-terminal tryptophan-based motif. J. Cell Sci. 127 (Pt 14 ), 3131–3140. 10.1242/jcs.148478 24829147
Vainio P. J. Viluksela M. Tuominen R. K. (1998). Nicotine-like effects of cotinine on protein kinase C activity and noradrenaline release in bovine adrenal chromaffin cells. J. Auton. Pharmacol. 18 245–250.9788295
Vallee A. Vallee J. N. Lecarpentier Y. (2021). Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/beta-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells 10 :230 . 10.3390/cells10020230 33503974
Van Beek A. H. Claassen J. A. (2011). The cerebrovascular role of the cholinergic neural system in Alzheimer’s disease. Behav. Brain Res. 221 537–542. 10.1016/j.bbr.2009.12.047 20060023
van Nuland A. J. M. den Ouden H. E. M. Zach H. Dirkx M. F. M. van Asten J. J. A. Scheenen T. W. J. (2020). GABAergic changes in the thalamocortical circuit in Parkinson’s disease. Hum. Brain Mapp. 41 1017–1029. 10.1002/hbm.24857 31721369
Vanhauwaert R. Verstreken P. (2015). Flies with Parkinson’s disease. Exp. Neurol. 274 42–51. 10.1016/j.expneurol.2015.02.020 25708988
Venkateshappa C. Harish G. Mythri R. B. Mahadevan A. Bharath M. M. Shankar S. K. (2012). Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem. Res. 37 358–369. 10.1007/s11064-011-0619-7 21971758
Videira P. A. Q. Castro-Caldas M. (2018). Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. Front. Neurosci. 12 :381 . 10.3389/fnins.2018.00381 29930494
Walker L. Stefanis L. Attems J. (2019). Clinical and neuropathological differences between Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies - current issues and future directions. J. Neurochem. 150 467–474. 10.1111/jnc.14698 30892688
Wang J. Y. Chen B. K. Wang Y. S. Tsai Y. T. Chen W. C. Chang W. C. (2012). Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. Cell Signal. 24 162–169. 10.1016/j.cellsig.2011.08.017 21924350
Wang M. Y. Meng M. Yang C. C. Zhang L. Li Y. L. Zhang L. (2020a). Cornel iridoid glycoside improves cognitive impairment induced by chronic cerebral hypoperfusion via activating PI3K/Akt/GSK-3beta/CREB pathway in rats. Behav. Brain Res. 379 :112319 . 10.1016/j.bbr.2019.112319 31669346
Wang X. Qiao Y. Dai Z. Sui N. Shen F. Zhang J. (2019). Medium spiny neurons of the anterior dorsomedial striatum mediate reversal learning in a cell-type-dependent manner. Brain Struct. Funct. 224 419–434. 10.1007/s00429-018-1780-4 30367246
Wang Y. Wang Y. Zhou M. Jiang D. Deng X. (2020b). Association of transferrin G258A and transferrin receptor A82G polymorphisms with the risk of Parkinson disease in certain area. Medicine 99 :e23432 . 10.1097/MD.0000000000023432 33235126
Wang Y. Yang Z. Le W. (2017). Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson’s Disease. Neurosci. Bull. 33 543–551. 10.1007/s12264-017-0160-z 28762215
Wang Y. Q. Qu D. H. Wang K. (2016). Therapeutic approaches to Alzheimer’s disease through stimulating of non-amyloidogenic processing of amyloid precursor protein. Eur. Rev. Med. Pharmacol. Sci. 20 2389–2403.27338066
Wayner M. J. Armstrong D. L. Phelix C. F. (1996). Nicotine blocks angiotensin II inhibition of LTP in the dentate gyrus. Peptides 17 1127–1133. 10.1016/s0196-9781(96)00179-9 8959746
Wess J. Eglen R. M. Gautam D. (2007). Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6 721–733. 10.1038/nrd2379 17762886
Wichmann T. (2018). Pathophysiologic Basis of Movement Disorders. Prog. Neurol. Surg. 33 13–24. 10.1159/000480718 29332070
Wichmann T. (2019). Changing views of the pathophysiology of Parkinsonism. Mov. Disord. 34 1130–1143. 10.1002/mds.27741 31216379
Wilson M. A. Fadel J. R. (2017). Cholinergic regulation of fear learning and extinction. J. Neurosci. Res. 95 836–852. 10.1002/jnr.23840 27704595
Wirdefeldt K. Adami H. O. Cole P. Trichopoulos D. Mandel J. (2011). Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. Epidemiol. 26 (Suppl. 1 ), S1–S58. 10.1007/s10654-011-9581-6 21626386
Wu J. Lukas R. J. (2011). Naturally-expressed nicotinic acetylcholine receptor subtypes. Biochem. Pharmacol. 82 800–807. 10.1016/j.bcp.2011.07.067 21787755
Wysocka A. Palasz E. Steczkowska M. Niewiadomska G. (2020). Dangerous Liaisons: Tau Interaction with Muscarinic Receptors. Curr. Alzheimer Res. 17 224–237. 10.2174/1567205017666200424134311 32329686
Yamamoto S. Nishiyama S. Kawamata M. Ohba H. Wakuda T. Takei N. (2011). Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](+)3-MPB and scopolamine in conscious monkeys. Neuropsychopharmacology 36 1455–1465. 10.1038/npp.2011.31 21430646
Yan Y. Beckley N. A. Kim V. J. Drenan R. M. (2019). Differential Nicotinic Modulation of Glutamatergic and GABAergic VTA Microcircuits. eNeuro 6 :2019 . 10.1523/ENEURO.0298-19.2019 31744841
Yan Z. Song W. J. Surmeier J. (1997). D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J. Neurophysiol. 77 1003–1015. 10.1152/jn.1997.77.2.1003 9065864
Ye B. S. Jeon S. Ham J. H. Lee J. J. Lee J. M. Lee H. S. (2017). Dementia-Predicting Cognitive Risk Score and Its Correlation with Cortical Thickness in Parkinson Disease. Dement. Geriatr. Cogn. Disord. 44 203–212. 10.1159/000479057 28930751
Yim S. H. Hee S. S. (1995). Genotoxicity of nicotine and cotinine in the bacterial luminescence test. Mutat. Res. 335 275–283.8524343
Yogev-Falach M. Amit T. Bar-Am O. Youdim M. B. (2003). The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17 2325–2327. 10.1096/fj.03-0078fje 14525944
Yoo H. S. Chung S. J. Lee Y. H. Ye B. S. Sohn Y. H. Lee P. H. (2019). Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson’s disease. J. Neurol. 266 1601–1610. 10.1007/s00415-019-09297-x 31011798
Zdanowski R. Krzyzowska M. Ujazdowska D. Lewicka A. Lewicki S. (2015). Role of alpha7 nicotinic receptor in the immune system and intracellular signaling pathways. Cent. Eur. J. Immunol. 40 373–379. 10.5114/ceji.2015.54602 26648784
Zeng X. S. Geng W. S. Jia J. J. Chen L. Zhang P. P. (2018). Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease. Front. Aging Neurosci. 10 :109 . 10.3389/fnagi.2018.00109 29719505
Zevin S. Jacob P. Geppetti P. Benowitz N. L. (2000). Clinical pharmacology of oral cotinine. Drug Alcohol. Depend 60 13–18.10821985
Zhai S. Shen W. Graves S. M. Surmeier D. J. (2019). Dopaminergic modulation of striatal function and Parkinson’s disease. J. Neural. Transm. 126 411–422. 10.1007/s00702-019-01997-y 30937538
Zhang D. Mallela A. Sohn D. Carroll F. I. Bencherif M. Letchworth S. (2013). Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson’s disease. J. Pharmacol. Exp. Ther. 347 225–234. 10.1124/jpet.113.207639 23902940
Zhang T. Chen D. Lee T. H. (2019). Phosphorylation Signaling in APP Processing in Alzheimer’s Disease. Int. J. Mol. Sci. 21 :209 . 10.3390/ijms21010209 31892243
Zhao J. Yu S. Zheng Y. Yang H. Zhang J. (2017). Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease. Mol. Neurobiol. 54 1404–1418. 10.1007/s12035-016-9743-3 26843115
Zheng B. Liao Z. Locascio J. J. Lesniak K. A. Roderick S. S. Watt M. L. (2010). PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2 :59 . 10.1126/scitranslmed.3001059 20926834
Zhou F. M. Wilson C. Dani J. A. (2003). Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9 23–36.12580337
Zhu Z. Yin J. Guan J. Hu B. Niu X. Jin D. (2014). Lithium stimulates human bone marrow derived mesenchymal stem cell proliferation through GSK-3beta-dependent beta-catenin/Wnt pathway activation. FEBS J. 281 5371–5389. 10.1111/febs.13081 25265417
Zoccolella S. Martino D. Defazio G. Lamberti P. Livrea P. (2006). Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses. Curr. Vasc. Pharmacol. 4 237–243. 10.2174/157016106777698414 16842141
Zou J. Chen Z. Liang C. Fu Y. Wei X. Lu J. (2018). Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson’s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage. Aging Dis. 9 51–65. 10.14336/AD.2017.0416 29392081
Ztaou S. Amalric M. (2019). Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s disease. Neurochem. Int. 126 1–10. 10.1016/j.neuint.2019.02.019 30825602
Zuchner T. Perez-Polo J. R. Schliebs R. (2004). Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J. Neurosci. Res. 77 250–257. 10.1002/jnr.20152 15211591

